<SEC-DOCUMENT>0001193125-16-795948.txt : 20161216
<SEC-HEADER>0001193125-16-795948.hdr.sgml : 20161216
<ACCEPTANCE-DATETIME>20161216172431
ACCESSION NUMBER:		0001193125-16-795948
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20161215
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161216
DATE AS OF CHANGE:		20161216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CRISPR Therapeutics AG
		CENTRAL INDEX KEY:			0001674416
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				473173478
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37923
		FILM NUMBER:		162057181

	BUSINESS ADDRESS:	
		STREET 1:		AESCHENVORSTADT 36
		CITY:			BASEL
		STATE:			V8
		ZIP:			4051
		BUSINESS PHONE:		6173154600

	MAIL ADDRESS:	
		STREET 1:		AESCHENVORSTADT 36
		CITY:			BASEL
		STATE:			V8
		ZIP:			4051
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d283294d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;15, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CRISPR THERAPEUTICS AG </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Company as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Switzerland</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-37923</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Aeschenvorstadt 36 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4051 Basel </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Switzerland
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>+41 61 228 7800 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction A.2. below):
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1.01.&nbsp;Entry Into a Material Definitive Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2016, CRISPR Therapeutics AG (&#147;CRISPR&#148;) entered into a Consent to Assignments, Licensing and Common Ownership
and Invention Management Agreement (the &#147;Invention Management Agreement&#148; or &#147;IMA&#148;) with The Regents of the University of California (&#147;California&#148;), University of Vienna (&#147;Vienna&#148;), Dr.&nbsp;Emmanuelle
Charpentier, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., ERS Genomics Ltd. (&#147;ERS&#148;), and TRACR Hematology Ltd. (&#147;TRACR&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under an existing license agreement (the &#147;Charpentier License&#148;), CRISPR licenses from Dr.&nbsp;Charpentier certain development
rights in a patent and patent applications related to CRISPR/Cas9 technology <FONT STYLE="white-space:nowrap">co-owned</FONT> by Dr.&nbsp;Charpentier. Under the Invention Management Agreement, California and Vienna retroactively consent to
Dr.&nbsp;Charpentier&#146;s licensing of her rights to the CRISPR/Cas9 intellectual property to CRISPR, our wholly-owned subsidiary TRACR, and ERS, in the United States and globally. The Invention Management Agreement also provides retroactive
consent of <FONT STYLE="white-space:nowrap">co-owners</FONT> to sublicenses granted by CRISPR, TRACR and other licensees, prospective consent to sublicenses they may grant in future, retroactive approval of prior assignments by certain parties, and
provides for, among other things, (i)&nbsp;good faith cooperation among the parties regarding patent maintenance, defense and prosecution, (ii)&nbsp;cost-sharing arrangements, and (iii)&nbsp;notice of and coordination in the event of third-party
infringement of the subject patents and with respect to certain adverse claimants of the CRISPR/Cas9 intellectual property. Unless earlier terminated by the parties, the Invention Management Agreement will continue in effect until the later of the
last expiration date of the patents underlying the CRISPR/Cas9 technology, or the date on which the last underlying patent application is abandoned. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 7.01. Regulation FD Disclosure. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December 16, 2016 CRISPR released a press release regarding its entry into the IMA. A copy of the press release is furnished herewith as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01 shall not be deemed &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as
expressly set forth by specific reference in such a filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Information. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our Joint Venture Agreement with Bayer Healthcare, LLC, and Casebia Therapeutics, LP the joint venture created thereunder,
Casebia is required to pay us an additional $15&nbsp;million technology access fee based on our entry into the IMA which allows us to commercialize CRISPR/Cas9 based therapies in countries outside of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01.&nbsp;Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following exhibits shall
be deemed to be furnished, and not filed: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Editing, dated December&nbsp;15, 2016, by and among CRISPR Therapeutics AG, The Regents
of the University of California, University of Vienna, Dr.&nbsp;Emmanuelle Charpentier, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., ERS Genomics Ltd., and TRACR Hematology Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by CRISPR Therapeutics AG, dated December&nbsp;16, 2016</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"><I>Certain confidential information contained in this exhibit was omitted by means of redacting a portion of the text and replacing it with </I><B><I>[***]</I></B><I>. This exhibit has been filed separately with the SEC
without the redaction pursuant to a Confidential Treatment Request under Rule <FONT STYLE="white-space:nowrap">24b-2</FONT> of the Securities Exchange Act of 1934, as amended.</I> </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">CRISPR THERAPEUTICS AG</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: December&nbsp;16, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Becker</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marc Becker</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Editing, dated December&nbsp;15, 2016, by and among CRISPR Therapeutics AG, The Regents
of the University of California, University of Vienna, Dr.&nbsp;Emmanuelle Charpentier, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., ERS Genomics Ltd., and TRACR Hematology Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by CRISPR Therapeutics AG, dated December&nbsp;16, 2016</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Certain confidential information contained in this exhibit was omitted by means of redacting a portion of the text and replacing it with </I><B><I>[***]</I></B><I>. This exhibit has been filed separately with the SEC
without the redaction pursuant to a Confidential Treatment R</I><I>equest under Rule <FONT STYLE="white-space:nowrap">24b-2</FONT> of the Securities Exchange Act of 1934, as amended.</I> </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d283294dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE <FONT STYLE="white-space:nowrap">24b-2</FONT> PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT TO ASSIGNMENTS, LICENSING
AND COMMON OWNERSHIP AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVENTION MANAGEMENT AGREEMENT FOR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A PROGRAMMABLE DNA RESTRICTION ENZYME FOR GENOME EDITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">UC Case No: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BK-2012-115</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CRISPR Reference: CHARPENTIER-2012 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Caribou Reference: <FONT STYLE="white-space:nowrap">UC-UV</FONT> Agreement </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Consent to Assignments,
Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Editing (the &#147;<U>Invention Management Agreement</U>,&#148; &#147;<U>IMA</U>&#148; or &#147;<U>Agreement</U>&#148;) is
effective as of December&nbsp;15, 2016 (the &#147;<U>Effective Date</U>&#148;), and is by and among the following individual and entities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Emmanuelle Charpentier, an individual having an address at the Max Planck Institute for Infection Biology, Department
of Regulation in Infection Biology, Chariteplatz 1, 10117 Berlin, Germany, (&#147;<U>Charpentier</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Regents
of the University of California, a California public corporation, having its statewide administrative offices located at 1111 Franklin Street, Twelfth Floor, Oakland, CA 946075200, United States, acting through its Office of Technology Licensing, at
the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347, United States (&#147;<U>Regents</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">University of Vienna, having an address at Universitatsring 1, <FONT STYLE="white-space:nowrap">A-1010</FONT> Vienna, Austria,
acting through its office of Research Services and Career Development, University of Vienna, Berggasse 7, 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> floor, 1090 Vienna, Austria (&#147;<U>Vienna</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">CRISPR Therapeutics AG, a Swiss company (Aktiengesellschaft) having an address at Aeschenvorstadt 36, <FONT
STYLE="white-space:nowrap">CH-4051</FONT> Basel, Switzerland (&#147;<U>CRISPR</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ERS Genomics Ltd., a limited
liability company incorporated in Ireland and having an address at 88 Harcourt Street, Dublin 2, Ireland (&#147;<U>ERS</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">TRACR Hematology Ltd., a limited liability company incorporated in England&nbsp;&amp; Wales and having an address at 85
Tottenham Court Road, London W1T 4TQ, United Kingdom (&#147;<U>TRACR</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Caribou Biosciences, Inc., a Delaware
corporation, having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710, United States (&#147;<U>Caribou</U>&#148;); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>1</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc., a Delaware corporation, having an address at 40 Erie Street,
Suite 130, Cambridge, MA 02139, United States (&#147;<U>Intellia</U>&#148;); each of the foregoing is individually referred to as a &#147;<U>Party</U>&#148; to this Agreement, and collectively as &#147;<U>Parties</U>&#148; to this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PART A. </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>BACKGROUND AND RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-1.</FONT> As set forth herein, all the Parties have certain interests in the patents and patent
applications defined and set forth in <U>Exhibit&nbsp;A</U> (the &#147;<U>Patent Applications</U>&#148;), including technologies and/or products described or claimed in the Patent Applications (the &#147;<U>Inventions</U>&#148;), whether as
inventor(s) and/or <FONT STYLE="white-space:nowrap">co-inventor(s),</FONT> assignee(s), and/or licensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-2.</FONT> Charpentier has certain rights in the Patent Applications as an inventor and/or <FONT
STYLE="white-space:nowrap">co-inventor</FONT> thereof and has not assigned her rights in the Patent Applications to any entity or institution, such rights being referred to herein as &#147;<U>Charpentier&#146;s Rights</U>.&#148; Charpentier has
delegated her rights with respect to the development, management and enforcement of the Patent Applications (individually and collectively &#147;<U>Invention Management Rights</U>&#148;) to CRISPR and ERS. In particular, Charpentier has delegated to
CRISPR Invention Management Rights (including without limitation her rights of invention management under this Agreement as well as certain corresponding obligations including without limitation the duty to pay costs and fees associated with the
Patent Applications and related proceedings), except for certain Patent Applications for which ERS has been delegated Invention Management Rights by Charpentier (&#147;<U>ERS Patent Delegation</U>&#148; and
&#147;<U><FONT STYLE="white-space:nowrap">ERS-Delegated</FONT> Patent Applications</U>,&#148; each as described in <U>Exhibit B</U>). Each of CRISPR and ERS is referred to herein as a &#147;<U>Charpentier Delegee</U>&#148; and collectively as the
&#147;<U>Charpentier Delegees</U>.&#148; (For clarity, Charpentier has not delegated to TRACR any Invention Management Rights and TRACR is not a Charpentier Delegee.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-3.</FONT> Charpentier has exclusively licensed her commercialization rights in the Patent Applications,
including her rights to commercialize products and methods described and/or claimed in the Patent Applications, to CRISPR, ERS and TRACR (pursuant to the &#147;<U>CRISPR License,</U>&#148; the &#147;<U>ERS License</U>&#148; and the &#147;<U>TRACR
License</U>&#148;), each of CRISPR, ERS and TRACR being individually and collectively the &#147;<U>Charpentier Licensee(s)</U>&#148; and each of the CRISPR License, the ERS License and the TRACR License, being individually and collectively the
&#147;<U>Charpentier License(s)</U><U>,</U>&#148; each Charpentier License being subject to Charpentier&#146;s retained <FONT STYLE="white-space:nowrap">non-transferable</FONT> right, without the right for Charpentier to license or sublicense, for
her to use the Inventions for her own research purposes and in her own <FONT STYLE="white-space:nowrap">non-commercial</FONT> research collaborations to which she is party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-4.</FONT> Regents has certain rights in the Patent Applications as a
<FONT STYLE="white-space:nowrap">co-owner</FONT> by virtue of assignments (the &#147;<U>Assignments to Regents</U>&#148;) of any and all rights, title and interests of the following inventors and/or
<FONT STYLE="white-space:nowrap">co-inventors</FONT> in the Patent Applications (either directly, or through the Howard Hughes Medical Institute (&#147;<U>HHMI</U>&#148;) in the case of certain rights of Jennifer Doudna, Martin Jinek and Wendell
Lim): Jennifer Doudna, Martin Jinek, James H. Doudna Cate, Wendell Lim and/or Lei S. Qi (the &#147;<U>Regents Assignors</U>&#148;), such rights being referred to herein as &#147;<U>Regents&#146; Rights</U>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>2</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-5.</FONT> Vienna has certain rights in the Patent
Applications as a <FONT STYLE="white-space:nowrap">co-owner</FONT> by virtue of an assignment (the &#147;<U>Assignment to Vienna</U>&#148;) of any and all rights, title and interest of inventor and/or
<FONT STYLE="white-space:nowrap">co-inventor</FONT> Krzysztof Chylinski in the Patent Applications (the &#147;<U>Vienna Assignor</U>&#148;), such rights being referred to herein as &#147;<U>Vienna&#146;s Rights</U><U>.</U>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-6.</FONT> Regents&#146; Rights are subject to obligations to HHMI, and any license or sublicense to the
Regents&#146; Rights is subject to obligations to HHMI, including HHMI&#146;s <FONT STYLE="white-space:nowrap">paid-up,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> irrevocable license to use the Inventions for research purposes
(&#147;HHMI&#146;s Retained Rights&#148;), Regents&#146; Rights also are subject to the U.S. Government rights, as described in 35 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">200-212,</FONT> and Regents&#146; Rights and Vienna&#146;s Rights
are subject to a retained right to practice the Inventions on their own behalf and allow other educational and <FONT STYLE="white-space:nowrap">non-profit</FONT> institutions to use the Inventions for research and educational purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-7.</FONT> Regents represents its own interests with respect to Invention Management Rights in the Patent
Applications, and Regents has also been authorized by Vienna (under an &#147;<U>Inter-Institutional Agreement</U>,&#148; attached hereto as <U>Exhibit D</U>) to take the lead in management of patent prosecution and licensing with respect to the
Patent Applications on behalf of Vienna, and such Inter-Institutional Agreement is not affected by provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">A-8.</FONT> Regents and Vienna have exclusively licensed their commercialization rights in the Patent Applications pursuant to an agreement with Caribou (the &#147;<U>Caribou License</U>&#148;), and Caribou has granted a
sublicense of certain of its rights in a defined field of human therapeutics to Intellia (the &#147;<U>Intellia Sublicense</U>&#148;), the Caribou License and the Intellia Sublicense being individually and collectively the &#147;<U>Regents
License(s)</U>,&#148; and Caribou and Intellia being individually and collectively the &#147;<U>Regents Licensee(s).</U>&#148; Regents Licenses are not affected by any provision of this Agreement and, in the exercise of rights and performance of
obligations under this Agreement, Regents and Regents Licensees shall comply with all obligations in Regents Licenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">A-9.</FONT> Additionally, Caribou, Intellia and the Charpentier Licensees have granted sublicenses to the Patent Applications to other third parties, who are not parties to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-10.</FONT> Charpentier, Regents and Vienna are individually referred to as a &#147;<U><FONT
STYLE="white-space:nowrap">Co-Owner</FONT></U>&#148; and collectively as the &#147;<U><FONT STYLE="white-space:nowrap">Co-Owners</FONT></U>.&#148; Charpentier&#146;s Rights, Regents&#146; Rights, and Vienna&#146;s Rights are collectively referred to
as the &#147;<U>Patent Rights</U>.&#148; Each of Regents and CRISPR, or any of their authorized representatives, is sometimes individually referred to herein as an &#147;<U>Invention Manager</U>&#148; and collectively referred to herein as the
&#147;<U>Invention Managers</U>&#148;; provided, however, that ERS shall be the Invention Manager in the stead of CRISPR with respect to <FONT STYLE="white-space:nowrap">ERS-Delegated</FONT> Patent Applications and, in the case of <FONT
STYLE="white-space:nowrap">ERS-Delegated</FONT> Patent Applications, shall be deemed to be an Invention Manager together with Regents in connection with the procedures set forth under Section <FONT STYLE="white-space:nowrap">C-1.3(b)</FONT> and
mediation or arbitration under Section <FONT STYLE="white-space:nowrap">D-1.2.</FONT> Each of CRISPR, ERS, TRACR, Caribou and Intellia is sometimes individually referred to herein as a &#147;<U>Licensee</U>&#148; and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>3</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
multiply or collectively referred to herein as &#147;<U>Licensees</U>,&#148; and their licenses (i.e. the Charpentier Licenses and the Regents Licenses) are sometimes individually, multiply or
collectively referred to herein as &#147;<U>License(s)</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, it has been and it remains the mutual desire of the Parties to
enter into this Agreement to cooperate regarding development and management of the Patent Rights and to facilitate the full commercial exploitation of their rights in the Patent Applications, including by permitting the licensing and sublicensing of
the same in order to develop and market products based upon or employing the Inventions both in the United States and in other jurisdictions worldwide; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, and in consideration of the commitments provided herein, the Parties agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PART B. </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONSENT TO ASSIGNMENTS, LICENSING AND </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MAINTENANCE OF COMMON OWNERSHIP INTERESTS </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">B-1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>CONSENT TO ASSIGNMENTS</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">B-1.1</FONT> Charpentier
consents, retroactively to the greatest extent required and permitted by applicable laws in the jurisdictions in which the Patent Applications have been filed, to the Assignments to Regents by Regents Assignors, in each case without application of
any rights of accounting, compensation or remuneration or other consideration, reporting, notification, assignment <FONT STYLE="white-space:nowrap">&#147;buy-in&#148;</FONT> rights (e.g., rights of
<FONT STYLE="white-space:nowrap">pre-emption),</FONT> or other rights or qualifications reserved in connection with such assignments under applicable laws or governmental regulations (such rights collectively referred to as &#147;<U>Rights Arising
in Connection with Assignments</U>&#148;). To the extent that such consent to the Assignments to Regents cannot be applied retroactively in certain jurisdictions in which the Patent Applications have been filed, and/or additional documentation or
assistance is required in order to perfect such assignments of rights, Charpentier agrees to assist Regents as reasonably required and at its expense in the perfection of such assignments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">B-1.2</FONT> Charpentier consents, retroactively to the greatest extent required and permitted by applicable
laws in the jurisdictions in which the Patent Applications have been filed, to the Assignment to Vienna by the Vienna Assignor, in each case without application of any Rights Arising in Connection with Assignments. To the extent that such consent to
the Assignment to Vienna cannot be applied retroactively in certain jurisdictions in which the Patent Applications have been filed, and/or additional documentation or assistance is required in order to perfect such assignments of rights, Charpentier
agrees to assist Vienna as reasonably required and at its expense in the perfection of such assignment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">B-1.3</FONT> Going forward, and subject to any restrictions provided for in the Inter-Institutional Agreement
with respect to Vienna and Regents (which shall only have effect as between Vienna and Regents), each <FONT STYLE="white-space:nowrap">Co-Owner</FONT> permits each other <FONT STYLE="white-space:nowrap">Co-Owner</FONT> to assign its interests in the
Patent Applications without application of any Rights Arising in Connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>4</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Assignments, provided that (a)&nbsp;no assignment shall be permitted to be made to an Adverse Claimant (as defined in Section <FONT STYLE="white-space:nowrap">C-1.3)</FONT> except by mutual
agreement of all of the <FONT STYLE="white-space:nowrap">Co-Owners,</FONT> and (b) any assignee(s) must fully assume and agree to be bound by all of the assignor&#146;s obligations under this Agreement, to which they shall become a signatory, in
connection with which, each other <FONT STYLE="white-space:nowrap">Co-Owner</FONT> shall be deemed to have consented to such assignment (to the extent necessary in accordance with applicable laws in the jurisdictions in which the Patent Applications
have been filed) and shall provide any additional documentation or assistance required in order to perfect such assignment of rights, and assist as reasonably required by the assignor, at the assignor&#146;s expense, in the perfection of such
assignment. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">B-2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>CONSENT TO LICENSING AND SUBLICENSING</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">B-2.1</FONT> The
Co-Owners provide the following consents: (a) Charpentier consents (i) to Regents&#146; and Vienna&#146;s grant of a license to Caribou under Regents&#146; Rights and Vienna&#146;s Rights to research, develop, make, have made, use, sell, have sold,
offer for sale, import and practice (individually and collectively to &#147;<U>Commercialize</U>&#148;) Inventions, subject to any limitations and qualifications contained in the Caribou License, and (ii)<U></U>&nbsp;to Caribou&#146;s grant of a
sublicense of certain of its rights to Intellia, subject to any limitations and qualifications contained in the Intellia Sublicense, and to any further grants of sublicenses pursuant to the Caribou License or the Intellia Sublicense; (b)<U></U>
Regents and Vienna consent to Charpentier&#146;s grant of licenses to CRISPR, TRACR and ERS under Charpentier&#146;s Rights to Commercialize Inventions, subject to any limitations and qualifications contained in the CRISPR License, the TRACR License
and the ERS License, respectively, and consent to any sublicenses granted pursuant to the Charpentier Licenses, and to any further grants of sublicenses pursuant to such licenses or sublicenses; (c) all of the
<FONT STYLE="white-space:nowrap">Co-Owners</FONT> agree that going forward, each of the <FONT STYLE="white-space:nowrap">Co-Owners</FONT> may provide licenses under their rights in the Patent Applications and/or transfer or otherwise modify such
licenses without requirement for any further consent of the other <FONT STYLE="white-space:nowrap">Co-Owners;</FONT> (d)<U></U> each licensee of a <FONT STYLE="white-space:nowrap">Co-Owner</FONT> and each of their sublicensees shall be entitled to
sublicense through multiple tiers, subject to any restrictions provided in their individual licenses and/or sublicenses and/or the Inter-Institutional Agreement with respect to Vienna and Regents, and provided that for each license or sublicense of
Regents&#146; rights, such license or sublicense shall include licensing terms as are required pursuant to the Regents&#146; agreement with HHMI; and (e)<U></U>&nbsp;except as explicitly provided herein no accounting, compensation or remuneration or
other consideration, reporting, or notification, is owed, or shall be owed, by one <FONT STYLE="white-space:nowrap">Co-Owner</FONT> or by its licensees or sublicensees to the other <FONT STYLE="white-space:nowrap">Co-Owners</FONT> or to their
licensees or sublicensees for prior or future licensing and sublicensing of the Patent Applications; provided that in connection with the foregoing consents by the <FONT STYLE="white-space:nowrap">Co-Owners</FONT> under <FONT
STYLE="white-space:nowrap">(a-d),</FONT> each <FONT STYLE="white-space:nowrap">Co-Owner</FONT> does not by virtue of this Section <FONT STYLE="white-space:nowrap">B-2.1</FONT> consent to any licensing, sublicensing or transfer of the Patent Rights
by the other <FONT STYLE="white-space:nowrap">Co-Owners</FONT> or their licensees or sublicensees, past or future, to an Adverse Claimant (as defined in Section <FONT STYLE="white-space:nowrap">C-1.3),</FONT> with respect to any Patent Rights, other
than in accordance with the provisions set forth in Section <FONT STYLE="white-space:nowrap">C-1.3(b);</FONT> and provided further that if any of the preceding consents cannot be granted prospectively in any particular jurisdiction in which the
Patent Applications have been filed, and/or additional documentation or assistance is required in connection with approval of such licenses and sublicenses, each <FONT STYLE="white-space:nowrap">Co-Owner</FONT> and (if applicable) other Party agrees
to provide such consents when and as required, [***] in connection with the approval of such licenses or sublicenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>5</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">B-2.2</FONT> The foregoing consents, to the extent they
apply to licenses or sublicenses already provided (&#147;<U>Preexisting Licenses and Sublicenses</U>&#148;), shall be deemed to apply retroactively to the greatest extent permitted by applicable laws in the jurisdictions in which the Patent
Applications have been filed, in each case without application of any rights of <FONT STYLE="white-space:nowrap">Co-Owners</FONT> with respect to accounting, compensation or remuneration or other consideration, reporting, notification, or other
rights or qualifications reserved in connection with such licenses under applicable laws or governmental regulations. To the extent that such consent to the Preexisting Licenses and Sublicenses cannot be applied retroactively in certain
jurisdictions in which the Patent Applications have been filed, and/or additional documentation or assistance is required in connection with approval of such licenses or sublicenses, each <FONT STYLE="white-space:nowrap">Co-Owner</FONT> and (if
applicable) other Party agrees to provide such consents when and as required, [***] in connection with the approval of such licenses and sublicenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">B-2.3</FONT> Subject to the foregoing and with regard to exclusivity, Regents and/or Vienna and/or their
licensees or sublicensees are permitted to have granted and to grant licenses and sublicenses that are &#147;exclusive&#148; (whether in general or by a field of the Patent Rights (a &#147;<U>Field</U>&#148;) or territory for example) by such
licensor(s) solely as to rights held by them, and Charpentier&#146;s consent to such license(s) and sublicense(s) as provided herein shall neither exclude nor limit Charpentier&#146;s or Charpentier&#146;s Licensees&#146; rights to practice and/or
Commercialize Inventions (including without limitation the granting of licenses and sublicenses through multiple tiers as contemplated in this Section <FONT STYLE="white-space:nowrap">B-2);</FONT> and similarly Charpentier and/or her licensees or
sublicensees are permitted to have granted and to grant licenses that are exclusive by such licensor(s) as to rights held by them, and Regents&#146; and Vienna&#146;s consents to such license(s) as provided herein shall neither exclude nor limit
Regents&#146; or Vienna&#146;s or Regents Licensees&#146; rights to practice and/or Commercialize Inventions (including without limitation the granting of licenses and sublicenses through multiple tiers as contemplated in this <FONT
STYLE="white-space:nowrap">Section&nbsp;B-2.</FONT> The resulting holders of licenses or sublicenses with overlapping or <FONT STYLE="white-space:nowrap">co-extensive</FONT> exclusive scope (whether in general or by particular field or territory for
example) originating from both Regents and Vienna on the one hand and Charpentier on the other hand are regarded as <FONT STYLE="white-space:nowrap">co-exclusive</FONT> licensee(s) or sublicensee(s)
(&#147;<U><FONT STYLE="white-space:nowrap">Co-Exclusive</FONT> Licensee(s)</U>&#148;) for purposes of this Agreement. For the avoidance of doubt, such <FONT STYLE="white-space:nowrap">Co-Exclusive</FONT> Licensee(s) shall be free (to the extent
empowered by their own rights) to practice and/or Commercialize Inventions but shall not be required to enter into agreements among themselves and/or with current or prospective licensees or sublicensees to effectively provide individual licensees
and/or sublicensees with additional levels of exclusivity or <FONT STYLE="white-space:nowrap">co-exclusivity</FONT> by such mutual agreements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">B-3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>MAINTENANCE OF COMMON OWNERSHIP INTERESTS</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">B-3.1</FONT>
It is the understanding and intent of the <FONT STYLE="white-space:nowrap">Co-Owners</FONT> that the Patent Applications have been and will continue to be jointly owned among them regardless of inventorship, which understanding and intent are
reflected in the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Party
hereby consents to, if and to the extent required in any and all applicable jurisdictions, and agrees to provide any required assistance to the <FONT STYLE="white-space:nowrap">Co-Owner(s)</FONT> to enable them to provide the applicable assignment
or license to the <FONT STYLE="white-space:nowrap">Co-Owners</FONT> jointly in accordance with Section <FONT STYLE="white-space:nowrap">B-3.1(b)(i)</FONT> and (ii), respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>6</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">B-4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>RESPONSIBILITIES AND COOPERATION OF <FONT STYLE="white-space:nowrap">CO-OWNERS</FONT></B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">B-4.1</FONT> The responsibilities of Charpentier, UC and Vienna in their capacities as <FONT STYLE="white-space:nowrap">Co-Owners</FONT> are as defined in this Part B. Charpentier, UC and Vienna shall execute any documents
(including without limitation terminal disclaimers) and provide any assistance in their capacities as <FONT STYLE="white-space:nowrap">Co-Owners</FONT> as may be required in order to effectuate the Invention Management Activities jointly approved by
the Invention Managers, or alternatively through dispute resolution, as described in Part C and Section <FONT STYLE="white-space:nowrap">D-1,</FONT> respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">B-5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>PROMOTION OF SCIENCE</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">B-5.1</FONT> A common goal of the
Parties is to promote the progress of science and the useful arts, and nothing in this Agreement is intended to impair or prevent the Parties from licensing, sublicensing and/or assigning the Inventions in a manner that does so. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PART C. </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INVENTION MANAGEMENT ACTIVITIES </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">C-1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>DEVELOPMENT AND DEFENSE OF THE PATENT APPLICATIONS</B> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-1.1</FONT> The Invention Managers will cooperate in good faith regarding the development and defense of the
Patent Applications, including without limitation filing, prosecution, issuance, and maintenance of Patent Applications, as well as interferences, oppositions, reissues, reexaminations, derivations, inter partes reviews, post-grant reviews, and
other post-grant proceedings in the U.S. or foreign patent offices involving any Patent Applications; revocation, cancellation, or nullity actions involving any Patent Applications that do not involve issues of infringement; and patent term
restorations, patent term adjustments and patent term extensions involving any Patent Applications (individually and collectively the &#147;<U>Patent Activities</U>&#148;); provided, however, that in no event will a Party be required to join as a
named party in any suit, counterclaim or other proceeding, absent a separate written agreement, into which a Party in its sole discretion may enter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-1.2</FONT> Regents, on behalf of itself and Vienna, shall have the right to appoint one U.S. law firm for
U.S. prosecution and for developing and transmitting instructions to foreign counsel (as provided below), and one U.S. interference law firm in connection with the shared rights of the Patent Applications (&#147;<U>Regents <FONT
STYLE="white-space:nowrap">Co-Counsel</FONT></U>&#148;). CRISPR, on behalf of itself and Charpentier and ERS, shall have the right to appoint one U.S. law firm for U.S. prosecution and for developing instructions to be transmitted by Regents <FONT
STYLE="white-space:nowrap">Co-Counsel</FONT> to foreign counsel (as provided below), and one U.S. interference law firm in connection with the shared rights of the Patent Applications (&#147;<U>Charpentier
<FONT STYLE="white-space:nowrap">Co-Counsel</FONT></U>&#148;); provided, however, that in connection with the prosecution of <FONT STYLE="white-space:nowrap">ERS-Delegated</FONT> Patent Applications and/or interference proceedings directed to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>7</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">ERS-Delegated</FONT> Patent Applications, ERS, on behalf of itself and Charpentier and CRISPR, shall have the right to appoint one U.S. law firm for U.S.
prosecution and for developing instructions to be transmitted by Regents <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> to foreign counsel (as provided below) and/or one U.S. interference law firm in connection with the shared rights of such
Patent Applications (&#147;<U>ERS <FONT STYLE="white-space:nowrap">Co-Counsel</FONT></U>&#148;). Each of these law firms is referred to individually and collectively as &#147;<U><FONT STYLE="white-space:nowrap">Co-Counsel</FONT></U>.&#148; If any of
Regents, ERS or CRISPR is an Abandoning Party, as set forth in Section <FONT STYLE="white-space:nowrap">C-1.5,</FONT> then such Abandoning Party shall lose its rights under this Section <FONT STYLE="white-space:nowrap">C-1.2</FONT> to appoint its <FONT
STYLE="white-space:nowrap">Co-Counsel</FONT> with respect to such <FONT STYLE="white-space:nowrap">Non-elected</FONT> Patent or <FONT STYLE="white-space:nowrap">Non-elected</FONT> Application (as defined in Section
<FONT STYLE="white-space:nowrap">C-1.5),</FONT> and only the Prosecuting Party may appoint counsel to represent its interests in connection with such particular Patent Rights. In all cases, the Party entitled to appoint <FONT
STYLE="white-space:nowrap">Co-Counsel</FONT> shall have the right to replace its <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> at any time in its sole discretion or to have one law firm for both U.S. prosecution and U.S. interference matters. <FONT
STYLE="white-space:nowrap">Co-Counsel</FONT> will be directed by the Invention Managers and shall confer and endeavor to reach positions in furtherance of the Patenting Objectives (as defined in Section
<FONT STYLE="white-space:nowrap">C-1.4(b))</FONT> regarding the shared Patent Activities, including without limitation agreeing with respect to Regents <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> instructions to a single foreign counsel in
each applicable jurisdiction outside of the United States. Drafts, submissions, and correspondence and any supporting documents or information pertaining thereto relating to Patent Activities (&#147;<U>Prosecution Matters</U>&#148;) will be supplied
to, or made available to be reviewed, by all Parties and Parties counsel (or, in the case of Prosecuting Parties pursuant to Section <FONT STYLE="white-space:nowrap">C-1.5,</FONT> the Parties having rights in such cases and their counsel), if
permitted pursuant to their License, provided that such communications being deemed (unless otherwise expressly provided by the participating Parties) to be <U>Common Interest Information</U> as defined in, and subject to, the CLIA (as defined in
Section <FONT STYLE="white-space:nowrap">D-4.1).</FONT> <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> shall consider and respond in good faith to timely received comments or questions from the Parties or their counsel regarding the Patent
Activities. Final submissions in any Prosecution Matter will be dependent upon approval by the Invention Managers (or, in the case of Prosecuting Parties pursuant to Section <FONT STYLE="white-space:nowrap">C-1.5,</FONT> the Parties having rights in
such cases), subject to the procedures of Section <FONT STYLE="white-space:nowrap">C-1.4</FONT> in the event of a failure to reach agreement on a particular course of action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-1.3</FONT> Certain third parties have filed and are pursuing patent applications identified in <U>Exhibit
E</U> that claim one or more of the Inventions (such third parties and their exclusive licensees being individually and collectively referred to as &#147;<U>Adverse Claimants</U>&#148; and such patent applications and/or resulting patents and their
foreign counterparts being individually and collectively referred to as &#147;<U>Adverse Filings</U>&#148;). In connection with the Adverse Claimants&#146; pursuit of Adverse Filings in the United States, one or more patent interferences may be
declared between or among one or more Patent Applications and one or more patents and/or patent applications comprising Adverse Filings, a first interference (Interference No.<U></U> 106,048) having recently been declared in connection with the
first issued U.S. patents comprising Adverse Filings. In addition, other adverse procedures or proceedings have already occurred and/or may occur in the United States and/or in other jurisdictions, including without limitation:
(i)<U></U>&nbsp;application of the Adverse Filings as allegedly anticipating and/or rendering obvious inventions claimed in the Patent Applications, (ii)<U></U> challenges by Adverse Claimants as to the patentability of one or more aspects of the
Patent Rights, (iii)<U></U>&nbsp;challenges by or assertions made by the Invention Managers as to priority of invention and/or patentability of one or more aspects of the Patent Applications <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">vis-a-vis</FONT></FONT> the Adverse Filings, and/or (iv)<U></U> challenges undertaken by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>8</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Invention Managers as to priority of invention and/or patentability of the Adverse Filings (individually and collectively &#147;<U>Adverse Proceedings</U>&#148;). In order to coordinate the
Patent Activities and promote the development and defense of the Patent Applications and/or the Patent Rights <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-a-vis</FONT></FONT> certain patent applications filed by third
parties that purport to claim one or more of the Inventions, and in consideration of the other commitments and obligations undertaken by the Parties to this Agreement, the Parties acknowledge and agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that the Invention Managers are successful in one or more of such Adverse Proceedings they undertake, and/or the Invention
Managers elect to settle one or more of such Adverse Proceedings, they shall establish terms of compensation by the Adverse Claimants and any of their licensees [***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Parties acknowledge and agree that their commitments to each other under this Agreement, including without limitation the consents
provided by each <FONT STYLE="white-space:nowrap">Co-Owner</FONT> to Licenses granted by other <FONT STYLE="white-space:nowrap">Co-Owner(s)</FONT> and to sublicenses granted by other <FONT STYLE="white-space:nowrap">Co-Owner(s)&#146;</FONT>
Licensee(s), in each case for the benefit of such other <FONT STYLE="white-space:nowrap">Co-Owner(s)</FONT> and their licensee(s) and sublicensee(s) and without any additional accounting, compensation or remuneration or other consideration,
reporting, or notification, the commitments to maintain common ownership regardless of inventorship, and the interests of the Parties and their respective licensee(s) and sublicensee(s) in the successful development and management of the Patent
Applications and in the success of the Adverse Proceedings initiated by or asserted against the <FONT STYLE="white-space:nowrap">Co-Owners,</FONT> are based in substantial part and dependent upon cooperation with respect to the Adverse Proceedings
and coordination with respect to Adverse Filings that are expressly related to the patentability or validity of the Patent Rights (including without limitation potential settlement and/or licensing discussions), and further acknowledge and agree
that their common interests with respect to the Adverse Proceedings and Adverse Filings could potentially become divergent and materially adverse to each other, and/or cooperation with respect to the Adverse Proceedings materially affected, in the
event that a Party unilaterally (i.e., without inclusion or agreement of other affected or potentially affected Parties) pursued or entered into an agreement (which shall include written and oral, binding and
<FONT STYLE="white-space:nowrap">non-binding</FONT> contracts, licenses, term sheets, options and any other form of agreement that could be legally considered such) related to the Patent Applications or Adverse Filings with an Adverse Claimant (or
an individual or entity holding some or all of an Adverse Claimant&#146;s proprietary interests in the Adverse Filings as a transferee or licensee with rights to grant licenses in the Adverse Filings) (a &#147;<U>Unilateral Transaction with Adverse
Claimants</U>&#148;) during the pendency of any Adverse Proceedings or their potential appeal, until the last final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision by an applicable court, agency, or similar binding dispute
resolution organization making a determination regarding the last Adverse Proceeding (the &#147;<U>T</U><U>erm of the Adverse Proceedings</U>&#148;), and accordingly the Parties agree that they have not concluded and will only engage in such
settlement, licensing or other discussions (&#147;<U>Resolution</U>&#148;) related to or enter into a Unilateral Transaction with Adverse Claimants during the Term of the Adverse Proceedings as follows: (i) [***]; (ii) [***]; or (iii) [***];
provided further that, in each of these cases, the Parties engaged in the Resolution (the &#147;<U>Resolution Parties</U>&#148;) [***]. For the avoidance of doubt, notwithstanding this Section <FONT STYLE="white-space:nowrap">C-1.3</FONT> or any
other provision of this Agreement, other than a Unilateral Transaction with an Adverse Claimant during the Term of the Adverse Proceedings, each Party shall be free to enter into any agreement with an Adverse Claimant; and,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>9</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
further, with the exception of interferences involving the Patent Rights and the Adverse Filings, nothing in this Agreement shall prevent, or create a duty of coordination or cooperation upon,
any Party from challenging the patentability, validity, enforceability or infringement of any Adverse Filing; and, further, that a licensee or sublicensee that is not a Party to this Agreement as defined on page 1 (or a majority-owned subsidiary or
other commonly-controlled affiliate of such a Party), such as a <FONT STYLE="white-space:nowrap">non-Party</FONT> sublicensee of one of the Parties to this Agreement, is not restricted in any way by, or subject to, Section <FONT
STYLE="white-space:nowrap">C-1.3</FONT> of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Failure to adhere to any of the commitments and undertakings of this
Section <FONT STYLE="white-space:nowrap">C-1.3</FONT> will be considered a material breach of this Agreement, for which any Party or Invention Manager may seek specific performance in accordance with the procedures of Section <FONT
STYLE="white-space:nowrap">D-1.2;</FONT> and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary in this Agreement, and in view of the
Parties&#146; common goal expressed in Section <FONT STYLE="white-space:nowrap">B-5.1,</FONT> nothing in this Agreement prevents, impairs or otherwise affects the ability of third-party beneficiary HHMI to enter into any agreement or arrangement
relating to scientific research involving HHMI or any of its officers, employees and/or agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-1.4</FONT> If the Invention Managers or Prosecuting Parties cannot agree regarding cooperation or a
proposed course of action as set forth in Sections <FONT STYLE="white-space:nowrap">C-1.1</FONT> through <FONT STYLE="white-space:nowrap">C-1.3,</FONT> as applicable, or on a costs and fees estimate as set forth in Section <FONT
STYLE="white-space:nowrap">C-2.1:</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Invention Managers will refer the disagreement to [***], or their equivalent, to discuss
in a good faith attempt to resolve the disagreement; provided, however, that any resolution shall not breach the Invention Managers&#146; respective Licenses without the prior written agreement from each Licensee that is a party to a License that
would be breached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Invention Managers still disagree after the discussion in Section
<FONT STYLE="white-space:nowrap">C-1.4(a),</FONT> they shall promptly and in good faith appoint mutually agreeable independent patent counsel (&#147;<U>Patent Rights Trustee</U>&#148;) neutral to the Parties, who will make the decision [***]
(individually and collectively the &#147;<U>Patenting Objectives</U>&#148;), and will consider, and to the extent reasonably advisable incorporate, the requests, comments, and suggestions of the Invention Managers. Regents on the one hand, and the
Charpentier Delegee on the other hand shall each pay such Patents Rights Trustee directly for [***] of all costs and expenses incurred by the Patent Rights Trustee. The Invention Managers may, by mutual written agreement, replace the Patent Rights
Trustee at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If action has to be taken by a <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> appointed under Section <FONT
STYLE="white-space:nowrap">C-1.2</FONT> in a short time frame in order to preserve rights, including without limitation making timely filings within an administrative proceeding, such <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> shall use all
[***] efforts to immediately notify the Invention Managers and Patent Rights Trustee (if one has been selected), and, if due to time constraints it is not feasible to first obtain agreement of all Invention Managers or decision from the Patent
Rights Trustee, if the Invention Managers have not agreed on a response, such <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> will take such action as is required to preserve those rights in light of the previously agreed objectives of the
Invention Managers for that proceeding and the Patenting Objectives as specified in Section <FONT STYLE="white-space:nowrap">C-1.4(b).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>10</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-1.5</FONT> If an Invention Manager elects to not pursue
(through a decision to not nationalize or otherwise), to abandon, or to cease prosecution or maintenance of any Patent Application (each a &#147;<U><FONT STYLE="white-space:nowrap">Non-elected</FONT> Application</U>&#148; or &#147;<U><FONT
STYLE="white-space:nowrap">Non-elected</FONT> Patent</U>&#148;) in any country, either on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis or in connection with a divisional or other
continuing Patent Application that an Invention Manager does not wish to support and share responsibility for associated expenses, such Invention Manager (the &#147;<U>Abandoning Party</U>&#148;) will provide at least thirty (30)&nbsp;days&#146;
prior written notice to the other Invention Manager and all Parties of such intention to not pursue, to abandon, or to cease prosecution or maintenance, following which notification the Abandoning Party shall be under no continuing obligation to
share in future corresponding costs and expenses as provided under Section C-2. Following such written notification, the other Invention Manager (the &#147;<U>Prosecuting Party</U>&#148;) may elect to pursue or continue prosecution of and/or
maintenance of the <FONT STYLE="white-space:nowrap">Non-elected</FONT> <FONT STYLE="white-space:nowrap">Patent/Non-elected</FONT> Application at its sole cost and expense and the Abandoning Party (and its licensees and any sublicensees) shall have
no rights in the <FONT STYLE="white-space:nowrap">Non-elected</FONT> <FONT STYLE="white-space:nowrap">Patent/Non-elected</FONT> Application, subject only to Regents&#146; and Vienna&#146;s retained right to allow
<FONT STYLE="white-space:nowrap">non-profit</FONT> entities to use the Inventions for research and educational purposes, and further, with respect to Regents, subject to the rights of HHMI and the U.S. Government, if applicable, as provided in
Section <FONT STYLE="white-space:nowrap">A-6,</FONT> and Charpentier&#146;s retained right with respect to research activities of Charpentier as provided in Section <FONT STYLE="white-space:nowrap">A-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During the [***] phase of [***], Regents and CRISPR as Charpentier Delegee jointly elected certain
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries in which to pursue regional or national phase counterparts (the &#147;<U>Jointly Elected Jurisdictions</U>&#148; as identified in <U>Exhibit F</U>); and CRISPR as Charpentier Delegee elected
certain additional jurisdictions in which to pursue regional or national phase counterparts that Regents did not elect to enter (the &#147;<U>Additional Jurisdictions</U>&#148; as identified in <U>Exhibit F</U>). Regents has a <FONT
STYLE="white-space:nowrap">one-time</FONT> option to add the Additional Jurisdictions, exercisable during the [***] period following the Effective Date of this Agreement, by written notification to CRISPR, provided that Regents shall upon exercise
be responsible for [***] of all costs and fees incurred in connection with the Additional Jurisdictions at the time of exercising the option, and shall be responsible for [***] of such costs and fees on an ongoing basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that Regents does not exercise the option to add the Additional Jurisdictions, then CRISPR as Charpentier Delegee will be
responsible for [***] of the costs and fees incurred in connection with the Additional Jurisdictions and only Charpentier, CRISPR and other Charpentier Licensees and their sublicensees will have patent rights in such
<FONT STYLE="white-space:nowrap">non-elected</FONT> Additional Jurisdictions; provided, however, that the Charpentier Delegee shall apprise the other Invention Manager of any newly-cited art and any new arguments (i.e., those that are not
substantially repetitive of or consistent with arguments already made in connection with Patent Activities) to be made in connection with such Additional Jurisdiction patent applications and patents, and provide at least [***] advance written notice
with a copy of such proposed arguments so that the other Invention Managers have an opportunity to review and provide suggestions regarding said proposed arguments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-1.6</FONT> Notwithstanding any other provision of this Agreement, no Invention Manager may abandon the
prosecution or the maintenance of any of the Patent Applications without giving prior written notice to the other Invention Manager. Furthermore, and for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>11</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
avoidance of doubt, the provisions of Section <FONT STYLE="white-space:nowrap">C-1.5</FONT> shall not relieve any Party of any additional procedural requirements or other obligations it may have
to its licensor(s) with respect to the abandoning or ceasing of prosecution or maintenance of any Patent Application pursuant to its License or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-1.7</FONT> Applications for patent term extension, patent term restoration, SPCs (as defined in <U>Exhibit
C</U>), and listing in regulatory publications (such as the FDA Orange Book and any foreign equivalent) will be at the sole discretion of the Party whose approved product, or whose licensee&#146;s or sublicensee&#146;s approved product, is first
proposed and statutorily ready to be relied upon for such filings in a particular jurisdiction, after written notice to the other Parties. Any other Party will promptly execute any documents reasonably required to effect such applications. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">C-2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>COST SHARING</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-2.1</FONT> The Invention Managers will
discuss and agree on expected costs and fees of Regents <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> performing Patent Activities in accordance with the Patenting Objectives, based on [***] estimates of Regents
<FONT STYLE="white-space:nowrap">Co-Counsel,</FONT> and will establish and deliver to Caribou a corresponding budget for Patent Activities, which will be updated [***] in consultation with Regents <FONT STYLE="white-space:nowrap">Co-Counsel,</FONT>
subject to the procedures of Section <FONT STYLE="white-space:nowrap">C-1.4</FONT> in the event of a failure to reach agreement. Regents <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> shall notify the Invention Managers if the costs and fees are
expected to exceed an approved [***] budget and will confer and agree on any updates to the [***] budget, also subject to the procedures of Section <FONT STYLE="white-space:nowrap">C-1.4</FONT> in the event of a failure to reach agreement. Regents <FONT
STYLE="white-space:nowrap">Co-Counsel</FONT> shall use reasonable efforts not to exceed [***] budgets or updates, but the Parties recognize that it is impossible to predict with accuracy or control how Patent Activities will progress, or the costs
and fees that will be required to accomplish necessary tasks, and accordingly, notwithstanding any budget limitations, Regents <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> shall take such action as Regents
<FONT STYLE="white-space:nowrap">Co-Counsel</FONT> deems necessary in light of the previously-agreed objectives of the Invention Managers for a proceeding and the Patenting Objectives. Budgets and updates will be made available for review by all
Parties and shall be deemed to be <U>Common Interest Information</U> (as defined in the CLIA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-2.2</FONT> If and to the extent it has not already done so, CRISPR will pay [***] of costs and fees
associated with the Additional Jurisdictions within [***] of the Effective Date. CRISPR will pay [***] of such total within [***] (a) Regents&#146; decision to not exercise its option with respect to such Additional Jurisdictions under Section <FONT
STYLE="white-space:nowrap">C-1.5(a),</FONT> or (b) the termination of the option period. Within [***] of the exercise of its option with respect to such Additional Jurisdictions under Section <FONT STYLE="white-space:nowrap">C-1.5(a),</FONT> Regents
will pay [***] of costs and fees associated with the Additional Jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-2.3</FONT> In
accordance with, and subject to, a separate agreement by and between CRISPR and Caribou (&#147;<U>Cost-Sharing Agreement</U>,&#148; attached hereto as <U>Exhibit G</U>) that will be executed contemporaneously with the execution of this Agreement,
CRISPR, on its behalf and on behalf of Charpentier and ERS, agrees to reimburse, in the amounts set forth in the Cost-Sharing Agreement, Caribou for costs and fees associated with Patent Activities performed or to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>12</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be performed by Regent <FONT STYLE="white-space:nowrap">Co-Counsel</FONT> that Caribou has paid, or is required to pay Regents under the Caribou License. CRISPR and Caribou will promptly provide
the Parties with any amendments to the Cost-Sharing Agreement. Any material breach by CRISPR or Caribou of the Cost-Sharing Agreement also shall constitute a material breach of this Agreement. For avoidance of doubt, other than as set forth in the
Cost-Sharing Agreement or in their respective Licenses or by separate written agreement, no Party shall be responsible for paying the costs or fees of another Party&#146;s counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-2.4</FONT> In any country and/or for any divisional or continuing application, for which only one Invention
Manager undertakes Patent Activities pursuant to Section <FONT STYLE="white-space:nowrap">C-1.5,</FONT> the corresponding expenses and fees shall be [***], in accordance with Section <FONT STYLE="white-space:nowrap">C-1.5.</FONT> </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">C-3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>RECORDS AND REPORTS</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-3.1</FONT> Regents shall keep
complete, true, and accurate accounts of all expenses and shall permit the other Invention Manager to allow its agents or a certified public accounting firm that is reasonably acceptable to Regents to examine its books and records, and those of its
underlying billers in the case of rebilling, in order to verify the payments owing under this Agreement. The requesting Invention Manager shall pay the cost of each examination and shall request no more than [***] examination per [***], unless an
examination shall reveal a discrepancy of greater than [***], in which case Regents shall pay the cost of examination and the requesting Invention Manager shall be entitled to request [***] examinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-3.2</FONT> No less than [***] each [***] during the Term, Regents
<FONT STYLE="white-space:nowrap">Co-Counsel</FONT> responsible for Patent Activities, which as of the Effective Date of this Agreement is [***], shall deliver to the Invention Managers and Licensees a written report setting forth the status of all
Patent Applications; provided, however, if Regents are an Abandoning Party pursuant to Section <FONT STYLE="white-space:nowrap">C-1.5,</FONT> then the Prosecuting Party(ies)&#146; counsel shall deliver to Regents a written report setting forth the
status of the <FONT STYLE="white-space:nowrap">Non-elected</FONT> Application(s) or <FONT STYLE="white-space:nowrap">Non-elected</FONT> Patent also at no less than [***] each [***] during the Term. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">C-4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>PATENT INFRINGEMENT</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-4.1</FONT> In the event that an
Invention Manager or other Party (to the extent of the actual knowledge of the licensing professional responsible for administration of this Agreement) learns of the infringement of any of the Patent Rights that it deems to be substantial
(&#147;<U>Substantial Infringement</U>&#148;), such Invention Manager or other Party shall promptly notify all of the other Parties of such infringement by providing written evidence of the infringement (&#147;<U>Infringement Notice</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-4.2</FONT> If the efforts of the Invention Managers and/or other Parties, individually or jointly, are not
successful in abating such infringement within [***] after the Infringement Notice is sent, then each Invention Manager may (subject, in the case of Vienna, to limitations undertaken in connection with the Inter-Institutional Agreement between
Vienna and Regents; and, in the case of all Parties, subject to any rights, limitations and obligations that a Party may have in its License): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) [***]; and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>13</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) [***]; and/or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, in the event that a statute, regulation, or other legal provision (such as, for example, the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman), as amended, the Biologics Price Competition and Innovation Act, amended,
or similar laws outside of the United States) require that an infringement or similar action be commenced prior to the [***] period set forth above, the [***] period will be shortened to effectively be [***] prior to the final deadline imposed by
the applicable legal requirement. Within [***] days after the Infringement Notice, the Party seeking to shorten the [***] period due to an applicable legal requirement shall inform the other Parties of the need and basis for shortening the time
period. A Party will immediately forward to the other Parties any and all notices of infringement received pursuant to such regulatory procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">C-4.3 [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">C-4.4</FONT> A legal action brought pursuant to Section <FONT STYLE="white-space:nowrap">C-4.2</FONT> (&#147;<U>Legal Action</U>&#148;) will be at the full expense of [***], and all recoveries obtained as a result of any
Legal Action, whether by settlement or otherwise, will be shared according to the following order: (a)&nbsp;reimbursement of all costs [***]; provided that any separate agreements between particular Parties and their licensee(s) or sublicensee(s)
and/or <FONT STYLE="white-space:nowrap">Co-Exclusive</FONT> Licensee(s) related to the potential sharing of amounts received by them, and any separate agreements between Regents and HHMI related to sharing of costs, expenses and revenues, shall be
unaffected by the foregoing terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-4.5</FONT> [***]. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PART D. </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MISCELLANEOUS PROVISIONS </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">D-1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>GOVERNING LAWS AND DISPUTE RESOLUTION</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-1.1</FONT> The
scope and validity of any Patent Applications are governed by the applicable laws of the relevant jurisdiction to which the Patent Applications relate. This Agreement shall otherwise be governed by New York law, without regard to its conflict of
laws principles; provided that all Parties shall be entitled to all defenses available to it under New York law and, additionally, Regents shall also be entitled to all defenses available to it under California law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-1.2</FONT> Due to the nature and subject matter of this Agreement, as well as commitments already
undertaken by the Parties or which may be undertaken by the Parties with respect to their licensees, and by their licensees with respect to sublicensees, a termination of this Agreement for material breach by another Party would not place the <FONT
STYLE="white-space:nowrap">non-breaching</FONT> Parties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>14</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or their beneficiaries in the same or an equivalent position to that which they would be in without the breach. Accordingly, the Parties agree that specific performance is deemed to be the
appropriate remedy in order to ensure that the Parties&#146; respective commitments and obligations undertaken to each other, and for the further benefit of their licensees and sublicensees, be fulfilled as agreed to herein, absent the Parties&#146;
mutual agreement to another form of remedy or to an amendment to this Agreement. It is also the desire of the Parties to avoid the need to litigate in order to address any potential dispute between them regarding the subject matter of this
Agreement, which would likewise be expected to be significantly disruptive to the interests of the Parties and to their preexisting and future commitments with respect to, and the activities of, their licensees and sublicensees. Accordingly, in the
case of any dispute, claim or controversy arising under this Agreement, including any matter that is not resolved by the Parties and/or the Invention Managers, and/or the Patent Rights Trustee pursuant to the procedure specified in Section <FONT
STYLE="white-space:nowrap">C-1.4,</FONT> or in the event that the Invention Managers should be unable to reach agreement regarding the selection and appointment of a Patent Rights Trustee pursuant to Section
<FONT STYLE="white-space:nowrap">C-1.4(b),</FONT> or if the Patent Rights Trustee should be unable or unwilling to resolve a particular contested matter, each of the forgoing being an &#147;<U>Unresolved Dispute</U>,&#148; then the Invention
Managers shall participate in mediation designed to encourage them to settle the matter between them, and if the Invention Managers are unsuccessful in settling the matter through mediation, then the Invention Managers and other Parties shall submit
the matter to binding arbitration which shall be directed to ensure that the Invention Managers&#146; and other Parties&#146; specific commitments and obligations to each other are fulfilled as originally agreed herein and with consideration of the
Patenting Objectives as specified in Section <FONT STYLE="white-space:nowrap">C-1.4(b),</FONT> unless the Invention Managers and other Parties mutually agree to waive or modify any particular commitments or obligations as provided herein. Mediation
and arbitration shall be conducted in accordance with the rules and procedures as set forth in <U>Exhibit H</U> (Dispute Resolution); and for the avoidance of doubt, no Party shall initiate or pursue alternative legal proceedings or remedies in
connection with an Unresolved Dispute other than according to the procedures as set forth in Section <FONT STYLE="white-space:nowrap">C-1.4,</FONT> this Section <FONT STYLE="white-space:nowrap">D-1.2,</FONT> and the accompanying <U>Exhibit H</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-1.3</FONT> [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-1.4</FONT> Notwithstanding anything to the contrary in this Agreement, binding arbitration shall not be
effective as to any interests (including, without limitation, rights or obligations) of third-party beneficiary HHMI without HHMI&#146;s prior written consent to binding arbitration on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>15</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">D-2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>NOTICES</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-2.1</FONT> Any notice required or permitted
to be given to the Parties hereto is properly given if delivered, in writing, in person, sent by registered mail or courier, with copies by email (which shall not alone constitute notice), to the following addresses, or to such other addresses as
may be designated in writing by the Parties from time to time during the term of this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Prof. Dr.&nbsp;Emmanuelle Charpentier
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Max Planck Institute for Infection Biology </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Department of Regulation in Infection Biology </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Chariteplatz 1 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">10117 Berlin </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Germany </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(with copies by email
to: LEGAL@crisprtx.com and Legalnotices@ersgenomics.com) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">CRISPR Therapeutics AG </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Aeschenvorstadt 36 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">CH-4051</FONT> Basel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Switzerland </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(with a copy by email to: LEGAL@crisprtx.com) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">ERS Genomics Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">88 Harcourt
Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Dublin 2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Ireland
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(with a copy by email to: Legalnotices@ersgenomics.com) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">TRACR Hematology Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">85
Tottenham Court Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">London W1T 4TQ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">United Kingdom </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Chief
Legal Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(with a copy by email to: LEGAL@crisprtx.com) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Regents of the University of California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Office of Technology Licensing </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">2150 Shattuck Avenue, Suite 510 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Berkeley, CA 94704-1347 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">United
States </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(Case No. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">BK-2012-115)</FONT></FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">University of Vienna </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Research
Services and Career Development </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Berggasse 7, 2nd floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">1090 Vienna </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Austria </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Vice-Rector for Research and International Affairs </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(with a copy by email to: techtransfer@univie.ac.at) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>16</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Caribou Biosciences, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">2929 7<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, Suite 105 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Berkeley, CA 94710 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">United States
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Chief Legal Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(with a copy by email to: legalnotices@cariboubio.com) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">40
Erie Street, Suite 130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Cambridge, MA 02139 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">United States </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(with a copy by
email to: NTLANOTICE@intelliatx.com) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-2.2</FONT> If Regents or Vienna terminates their
Inter-Institutional Agreement, or if Charpentier, CRISPR or ERS materially change the rights or obligations of CRISPR or ERS as Invention Manager under this Agreement, they will promptly notify the other Parties of such change in writing, and the
Parties agree to amend this Agreement if and as necessary to reflect such change. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">D-3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>TERM AND TERMINATION</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-3.1</FONT> This Agreement is in
full force and effect from the Effective Date and remains in effect for the life of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> patent or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-be-abandoned</FONT></FONT></FONT> Patent Application, whichever is later (the &#147;<U>Term</U>&#148;), unless earlier terminated by operation of law or by agreement of the Parties.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">D-4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>CONFIDENTIALITY AND COMMON INTEREST INFORMATION</B> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-4.1</FONT> Subject to the California Public Records Act as it affects Regents, the Parties shall hold each
other&#146;s confidential and/or proprietary business and patent prosecution information in confidence using at least the same degree of care as that Party uses to protect its own confidential and/or proprietary information of a like nature, and
shall comply with their responsibilities under the Confidential Common Legal Interest and Nondisclosure Agreement, entered into as of [***], a copy of which is attached hereto as <U>Exhibit I</U>, as amended by the First Amendment to the
Confidential Common Legal Interest and Disclosure Agreement [***] (&#147;<U>CLIA</U>&#148;), [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-4.2</FONT> Notwithstanding Section <FONT STYLE="white-space:nowrap">D-4.1,</FONT> nothing in this Agreement
in any way restricts or impairs the right of Parties to use, disclose, or otherwise deal with any information or data that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) recipient
can demonstrate by written records was previously known to it; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) is now, or becomes in the future, public knowledge other than through
acts or omissions of recipient; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>17</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) is lawfully obtained without restrictions by recipient from sources independent of the
disclosing Party that were not under any obligations of confidentiality to the disclosing Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) was made independently without the
access to or use of proprietary information received hereunder as evidenced by contemporaneous written records; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) is required by law
to be disclosed, provided the Party required to disclose notifies the other Parties promptly upon learning about any legal requirement that purports to compel disclosure and thereafter cooperates with and assists the nondisclosing Parties in the
exercise of any rights to protect the confidentiality of all or portions of its confidential or proprietary information before any tribunal or governmental agency, and in the event disclosure is required to disclose only the minimum amount of
information required to be disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-4.3</FONT> The confidentiality obligations of the recipient
under these terms will remain in effect for [***] after the termination or expiration date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">D-4.4</FONT> This Agreement may be disclosed by a Party on a confidential basis, under terms no less restrictive than Section <FONT STYLE="white-space:nowrap">D-4.1,</FONT> to actual or potential contracting parties and
advisors (i.e., actual or potential licensees, investors, acquirors, joint venturers and the like, and/or auditors, counsel and financial or other advisors), and as required by applicable law or governmental regulation. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="white-space:nowrap">D-5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>MISCELLANEOUS PROVISIONS</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.1</FONT> <U>Use of Names
and Trademarks; Publicity.</U> This Agreement does not confer any right to use any name, trade name, trademark, or other designation of any Party to this Agreement (including contraction, abbreviation, or simulation of any of the foregoing) in
advertising, publicity, or other promotional activities, and the use of the name, &#147;The Regents of the University of California&#148; or the name of any campus of the University of California is prohibited in such contexts; provided that the
Parties agree to cooperate to develop agreed forms of language for press release and related publicity that may be employed by the Parties in connection with this Agreement, to which Regents and other Parties agree to be named as a party in
connection with this Agreement. The name, trade name, trademark, or other designation of HHMI in advertising, publicity or other promotional activities shall be not be used without HHMI&#146;s written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.2</FONT> <U>No Waiver or Amendment Other than in Writing.</U> No provision of or right under this
Agreement shall be deemed to have been waived or amended by any act or acquiescence on the part of any Party, or any of its licensees or sublicensees, directors, employees, consultants, advisors or agents, but only by an instrument in writing signed
by an authorized representative of each Party. No waiver by any Party of any breach of this Agreement by another Party shall be effective as to any other breach, whether of the same or any other term or condition and whether occurring before or
after the date of such waiver. The Parties irrevocably agree that this Agreement may only be amended by a writing executed by all of the Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>18</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.3</FONT> <U>No Implied License.</U> This Agreement does
not confer by implication, estoppel, or otherwise any license or rights under any patents of any Party other than the Patent Applications, regardless of whether such patents are dominant or subordinate to the Patent Applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.4</FONT> <U>No Joint Venture, Partnership or Ability to Bind Other Parties.</U> This Agreement does not
create by implication or otherwise any joint venture or partnership between or among the Parties, nor does it confer any authority to bind another Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.5</FONT> <U>Terminology and Interpretation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Headings and captions are for convenience only and are not be used in the interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may
require, any pronoun shall include the corresponding masculine, feminine, and neuter forms. The word &#147;will&#148; shall be construed to have the same meaning and effect as the word &#147;shall.&#148; The word &#147;any&#148; shall mean &#147;any
and all&#148; unless otherwise clearly indicated by context. The word &#147;including&#148; shall be construed as &#147;including without limitation,&#148; whether or not the latter is expressly stated. The word &#147;or&#148; is disjunctive but not
necessarily exclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Unless the context requires otherwise, (i)<U></U>&nbsp;any definition of or reference to any agreement,
instrument, or other document herein shall be construed as referring to such agreement, instrument, or other document as from time to time amended, supplemented, or otherwise modified (subject to any restrictions on such amendments, supplements, or
modifications set forth herein or therein), (ii) any reference to any applicable laws herein shall be construed as referring to such applicable laws as from time to time enacted, repealed, or amended, (iii)<U></U>&nbsp;any reference herein to any
person or entity shall be construed to include the person&#146;s or entity&#146;s successors and assigns, and (iv)<U></U>&nbsp;all references herein to Parts, Sections, or Exhibits, unless otherwise specifically provided, shall be construed to refer
to Parts, Sections, and Exhibits of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Each of the Parties acknowledges and agrees that this Agreement has been
diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel, and that the final agreement contained herein, including the language whereby it has been expressed,
represents the joint efforts of the Parties and their counsel. Accordingly, in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party as being responsible for the wording or drafting of this Agreement or
any such provision, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored such provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.6</FONT> <U>Complete Agreement</U>. Other than the Inter-Institutional Agreement (<U>Exhibit D</U>), the
CLIA (<U>Exhibit I</U>) and the Licenses, this Agreement (including <U>Exhibits A, B, C, E, F, G, H and J</U>) constitutes the entire agreement, both written and oral, by and among the Co-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>19</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Owners, and all other prior agreements regarding the subject matter of this Agreement, both written and oral, express or implied, are hereby cancelled. For the avoidance of doubt, this Agreement
does not affect any License. Additionally, as provided in Section <FONT STYLE="white-space:nowrap">A-6,</FONT> Regents&#146; Rights are subject to certain U.S. Government rights and also obligations to HHMI. Nothing in this Agreement affects such
U.S. Government rights. Nor does anything in this Agreement affect any rights or obligations as between HHMI and Regents under any other agreement, nor shall any assignment, license or sublicense granted pursuant to or as a result of this Agreement
limit HHMI&#146;s Retained Rights. Any assignment, license or sublicense of Regents&#146; Rights granted pursuant to or as a result of this Agreement shall, moreover, be reviewed by Regents or Regents Licensees, as appropriate, to ensure inclusion
of HHMI&#146;s licensing terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.7</FONT> <U>HHMI</U>. HHMI is not a party to this Agreement and has
no liability to the Parties under this Agreement or to any licensee, sublicensee or assignee of rights by virtue of this Agreement, but HHMI is an intended third-party beneficiary of, and has the right to enforce in its own name, any provision of
this Agreement affecting HHMI. This Section <FONT STYLE="white-space:nowrap">D-5.7</FONT> shall survive any termination or expiration of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.8</FONT> <U>Severability</U>. All of the covenants and provisions of this Agreement are severable. In the
event that any of these covenants or provisions shall for any reason be adjudged, decreed, or ordered by any arbitrator or court of competent jurisdiction to be invalid or unenforceable in any respect, such covenants or provisions shall be deemed
modified to the extent necessary to render them valid and enforceable, while maintaining the expressed intention of the parties to the greatest extent permissible, and such judgment, decree, or order shall not affect, impair or invalidate any of the
remaining covenants or provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.9</FONT> <U>Successors and Assignees</U>. This
Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective acquirors, successors (including any personal successors by law or otherwise), permitted assignees, heirs, executors, transferees, administrators,
receivers, or other corporate successors or representatives of the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">D-5.10</FONT>
<U>Authority</U>. Each <FONT STYLE="white-space:nowrap">Co-Owner</FONT> (to the extent of actual knowledge of the licensing professional responsible for the administration of this Agreement as of the Effective Date, as applicable) represents and
warrants that it currently owns the rights, title, and interest in and to the Patent Applications in order to carry out its undertakings to the other Parties and obligations hereunder. Each Party represents and warrants that this Agreement is
legally binding upon such Party, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which such Party is currently bound. Each Party agrees that it will not enter into
any agreement, instrument or understanding, oral or written, that is inconsistent with the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">D-5.11</FONT> <U>Counterparts</U>. This Agreement may be executed in counterparts (whether delivered by facsimile, electronically by image or PDF or otherwise) with the same effect as if each Party had executed the same
physical document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>20</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties hereto have executed this Agreement as of the Effective Date, as attested by the
signatures below of authorized representatives of each Party. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>DR. EMMANUELLE CHARPENTIER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Emmanuelle Charpentier</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Javed Afzal</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Javed Afzal</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Associate Director</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December 15, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December<U></U>&nbsp;6, 2016</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>UNIVERSITY OF VIENNA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CRISPR THERAPEUTICS AG</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Heinz Fassmann</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rodger Novak</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Heinz Fassmann</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Rodger Novak</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Vice Rector for Research and International Affairs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December<U></U> 6, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December<U></U> 13, 2016</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ERS GENOMICS LTD.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>TRACR HEMATOLOGY LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Derek O&#146;Reilly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tyler Dylan-Hyde</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Derek O&#146;Reilly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Tyler Dylan-Hyde</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chief Legal Officer</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December 6, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December<U></U>&nbsp;15, 2016</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CARIBOU BIOSCIENCES, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INTELLIA THERAPEUTICS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rachel E. Haurwitz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Nessan Bermingham</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Rachel E. Haurwitz, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Nessan Bermingham</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President and CEO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO and President</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December<U></U>&nbsp;2, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December<U></U>&nbsp;15, 2016</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>21</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Patent Applications</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ERS Patent Delegation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Definition of SPCs</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Inter-Institutional Agreement between The Regents of the University of California and University of Vienna (copy)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Adverse Claimants</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Filings</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit G</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cost-Sharing Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit H</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dispute Resolution</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit I</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Confidential Common Legal Interest and Nondisclosure Agreement (copy)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit J</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to the Confidential Common Legal Interest and Nondisclosure Agreement</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page <B>22</B> of <B>39</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Patent Applications </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent
Applications refer to any and all of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any of the following U.S. and PCT patent applications: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:87.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Patent Application Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:36.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Filing Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:56.90pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">UC Case Number</P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) any U.S. patent application that claims priority to or common priority with any of the above-referenced
patent applications, regardless of inventorship, including but not limited to, any divisions, continuations, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent applications claiming priority to or common priority with any of the
above-referenced patent applications, or constituting the national phase counterparts of the above-referenced PCT application, as well as divisionals or continuations of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent applications; </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) any U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patents issued from any of
the foregoing applications; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) any reissues, renewals, substitutions, registrations, revalidations, reexaminations, patent term
restorations, patent term extensions, patent term adjustments, supplementary protection certificates (&#147;SPCs&#148;) and the like arising from any of the foregoing cases. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ERS Patent Delegation </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ERS has
been delegated certain invention management rights by Charpentier (the &#147;ERS Patent Delegation&#148;) within the ERS field. The delegated rights are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Prosecution and maintenance rights for Patent Applications that have applicability or utility exclusively in the ERS field <FONT STYLE="white-space:nowrap">(&#147;ERS-Delegated</FONT> Patent Applications&#148;) and has
comment rights in respect of all other Patent Applications that have applicability or utility in the ERS field. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Patent enforcement rights in the ERS field for all Patent Applications including any Patent Applications that have applicability or utility in both the ERS and CRISPR/TRACR fields. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ERS field is [***]. The CRISPR and TRACR fields means: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Researching, developing, making, using or selling: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Therapeutic Products - [***], or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Diagnostic Products - [***]. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Companion Diagnostics means companion diagnostic tools and/or diagnostic assays
developed and used to (i) [***], (ii) [***], and/or (iii) [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Covered Product means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Covered Animal means an animal [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Covered Animal-Derived
Product means [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Covered Method means any process or method, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Invention means the invention entitled &#147;[***]&#148; as described in the Patent Applications, including all improvements thereto that are disclosed in the
Patent Applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Technology means the Invention, the Patent Applications and certain <FONT STYLE="white-space:nowrap">know-how.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit C to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Definition of SPCs </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>SPCs</U>&#148; refer to Supplementary Protection Certificates that extend patent terms based on regulatory filings for marketing authorization
undertaken and approved in the United Kingdom (UK), countries of the European Union (EU) and the European Economic Area (EEA) and certain other countries in Europe including, but not limited to, Switzerland, and equivalents thereto available in
other jurisdictions (including, but not limited to, Australia, Canada (effective with the Comprehensive Economic and Trade Agreement (CETA) implementation), Chile, Costa Rica, Israel, Japan, Russia and Commonwealth of Independent States (CIS)
countries, Singapore, South Korea and Taiwan), as well as &#147;pediatric extensions&#148; to SPC terms available in the UK, EU/EEA and other countries, and other such patent term extensions currently available or which become available during the
Term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit D to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Inter-Institutional Agreement between The Regents of the University of California and University of Vienna (copy) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit E to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Adverse Claimants </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Adverse
Claimants are the applicants and the direct, first-tier exclusive licensees of patent applications and/or issued patents claiming priority to or common priority with the applications identified below, which claim subject matter comprising all or
portions of the Patent Rights: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Patent</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Application</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman"><I>Number</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Filing Date /</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Claimed</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:42.80pt; font-size:8pt; font-family:Times New Roman"><I>Priority Date</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:30.15pt; font-size:8pt; font-family:Times New Roman"><I>Inventors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Applicant(s) / Direct, First-Tier</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Exclusive Licensee(s)</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:102.70pt; font-size:8pt; font-family:Times New Roman"><I>(known as of the Effective Date)</I></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and further including any U.S. patent application that claims priority to or common priority with such patent applications,
regardless of inventorship, including but not limited to, any divisions, continuations, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> thereof; any
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent applications claiming priority to or common priority with any of the above-referenced U.S. patent applications, or constituting the national phase counterparts of the above-referenced PCT
application, as well as divisionals or continuations of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent applications; and any U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patents issued thereon; as well as reissues,
renewals, substitutions, registrations, revalidations, reexaminations, patent term restorations, patent term extensions, patent term adjustments, SPCs arising from any of the preceding cases, and the like. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit F to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Filings </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Jointly Elected Jurisdictions</U>&#148; are the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;<U>Additional
Jurisdictions</U>&#148; are the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit G to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Cost-Sharing Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Cost-Sharing Agreement (&#147;Agreement&#148;), having a date of December 15, 2016 (&#147;Effective Date&#148;), is by and between CRISPR
Therapeutics AG, having a corporate address at Aeschenvorstadt 36, <FONT STYLE="white-space:nowrap">CH-4051</FONT> Basel, Switzerland (&#147;CRISPR&#148;), and Caribou Biosciences, Inc., having a corporate address at 2929 7<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Street, Suite 105, Berkeley, CA 94710 USA (&#147;Caribou&#148;). CRISPR and Caribou are each referred to as a &#147;Party,&#148; and jointly as the &#147;Parties.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, CRISPR and Caribou are parties to a Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a
Programmable DNA Restriction Enzyme for Genome Editing Agreement (&#147;IMA&#148;), to which this Agreement is attached as Exhibit G thereto and having the same date as this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to an Exclusive License Agreement, by and among Caribou, University of Vienna (&#147;Vienna&#148;), and The Regents of the
University of California (&#147;Regents&#148;), dated April&nbsp;16, 2013 (&#147;Caribou License&#148;), Caribou has been reimbursing and will continue to reimburse Regents for patent costs and attorney fees for prosecuting and maintaining the
Patent Applications (as defined in the IMA), including [***] relating to [***], as set forth in the Caribou License (collectively, &#147;Patent Costs&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date of this Agreement, [***] is Regents&#146; counsel for [***], and [***] is Regents&#146; counsel for all other Patent
Applications (collectively, &#147;Regents&#146; Counsel&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties desire to come to a resolution regarding
reimbursement of past and future Patent Costs of Regents&#146; Counsel; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual agreements
contained in this Agreement, and for good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Within [***] of the Effective Date of this Agreement, CRISPR will reimburse Caribou $[***], as an adjusted settlement of [***] of the
Patent Costs invoiced by UC and paid by Caribou during the period [***] through [***]. Caribou will provide wire instructions to CRISPR within [***] of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. For all invoices that Caribou received or will receive from UC for Patent Costs that were not paid by Caribou on or before [***], and which
are: (i)&nbsp;invoiced by UC to Caribou before [***], for which payment was not due until after [***]; (ii) invoiced by UC to Caribou after [***], but prior to the effective date of the IMA (whether or not payment was or is due before the effective
date of the IMA), or (iii)&nbsp;invoiced by UC to Caribou after the effective date of the IMA, Caribou will invoice CRISPR for [***] of the invoiced amount within [***] after Caribou&#146;s payment to Regents, together with a copy of the invoice(s)
received from Regents and proof of payment to Regents. Within [***] after receipt of each such Caribou invoice, CRISPR will wire the amount set forth on the invoice to Caribou. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. As long as CRISPR has and is making the timely payments as set forth in Sections 1 and 2,
Caribou will indemnify and defend CRISPR in any collection actions taken by Regents against CRISPR for Patent Costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. In the event that
Caribou is required to take legal action to collect amounts due to it by CRISPR under this Agreement, CRISPR will pay all costs, including attorneys&#146; fees, incurred in such collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Reimbursed Patent Costs shall not include fees or costs of attorneys retained by and/or representing CRISPR, Caribou, or any third party
(including but not limited to Emmanuelle Charpentier and ERS Genomics Ltd.). As of the Effective Date of this Agreement, Patent Costs include those of [***], [***], and all foreign associates prosecuting the Patent Applications under the instruction
of, and invoiced by, [***] (collectively and individually, the &#147;Foreign Associates&#148;), in accordance with Section C of the IMA. CRISPR acknowledges that Regents may, at its sole discretion, replace [***], [***], or any of the Foreign
Associates as Regents&#146; Counsel, and that, in such event, CRISPR&#146;s obligations with respect to the Patent Costs associated with replacement Regents&#146; Counsel (including Foreign Associates) shall be subject to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. This Agreement shall be governed in accordance with the Governing Laws and Dispute Resolution procedures as provided in Section D of the
IMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. This Agreement may be executed in any number of counterparts, including facsimile or scanned PDF documents. Each such
counterpart, facsimile, or scanned PDF document shall be deemed an original instrument and all of which together shall constitute one and the same Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Cost-Sharing Agreement to be executed by their respective authorized representations as of
the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CRISPR Therapeutics AG</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Caribou Biosciences, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rodger Novak</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rachel E. Haurwitz</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rodger Novak</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rachel E. Haurwitz, Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President&nbsp;&amp; Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December&nbsp;13, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">December&nbsp;2, 2016</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of Invoices to be delivered to:<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Legal@crisprtx.com</U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I><U>Finance@crisprtx.com</U></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of remittance statements to be delivered to:<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I><U>accounts.receivable@cariboubio.com</U></I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address for Notice:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Address for Notice:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRISPR Therapeutics Limited</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">85
Tottenham Court Road</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London W1T 4TQ</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United Kingdom</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Caribou Biosciences, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2929 7<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Street, Suite 105</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Berkeley, CA 94710</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">With a copy (which shall not constitute notice) to:<I> <U>Legal@crisprtx.com </U></I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">With a copy (which shall not constitute notice) to: <I>legalnotices@cariboubio.com </I></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit H to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Dispute Resolution </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes of
any nature between the Parties arising under this Agreement (a &#147;Dispute&#148;) will be resolved exclusively through mediation and binding arbitration as set forth in this Exhibit H (&#147;<U>Mediation/Arbitration</U>&#148;), including without
limitation the determination of the scope or applicability of this Agreement to arbitrate. The Parties agree and acknowledge that any good faith dispute in Mediation/Arbitration will not be deemed to be a material breach of this Agreement. For the
purposes of provisions (b)&nbsp;through (j), the term &#147;Parties&#148; shall mean the Parties involved in the Dispute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The Mediation/Arbitration
will be conducted in [***] and shall be administered by JAMS (formerly Judicial Arbitration and Mediation Services, Inc.) strictly in accordance with the below-described process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The Parties will appoint a single mediator and a single arbitrator to be selected by mutual agreement or, if the Parties are unable to agree on an
arbitrator within [***] after such matter is referred to Mediation/Arbitration (all days being calendar days unless otherwise specifically provided herein), the Parties will request that JAMS select the arbitrator, in each case satisfying the
criteria set forth below to the maximum extent possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) In all cases: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">involving a disagreement over patent matters (including without limitation the conduct of the Patent Activities), the arbitrator should be a patent attorney registered to practice by the U.S. Patent&nbsp;&amp; Trademark
Office with [***]; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">not involving patent matters patent matters, the arbitrator should be an attorney with [***]. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under no circumstances shall the arbitrator be a current or former employee or consultant of any of the Parties, an affiliated company that
controls or is controlled by or is under common control with any of the Parties, an exclusive licensee of any of the Parties, or a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licensee of any of the Parties that is involved in the dispute
or has a direct interest in its outcome. In all cases, the arbitrator shall be fluent in the English language. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Within [***] after such matter is referred to Mediation/Arbitration, each Party will provide the arbitrator with
its one proposed resolution and a written memorandum in support of its position regarding the Dispute and its proposed resolution (each an &#147;<U>Opening Brief</U>), which shall not exceed thirty (30)&nbsp;pages in total. In connection with the
submission of an Opening Brief, a Party may also submit documentary evidence in support thereof which had both (x)&nbsp;existed prior to commencement of such Mediation/Arbitration and (y)&nbsp;been shared with the other Parties at least [***] prior
to the date for submission of the Opening Brief. The arbitrator will provide each Party&#146;s Opening Brief, along with copies of any supporting documentation, to the other Parties
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
after he or she has received an Opening Briefs from all Parties. The arbitrator shall not consider any untimely Opening Brief(s) received after the arbitrator has provided copies of the Opening
Briefs received to the other Party(ies). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Within [***] after a Party receives another Party&#146;s Opening Brief from the arbitrator, such receiving Party will have the right to submit to the arbitrator a response to the other Party&#146;s Opening Brief (each,
a &#147;<U>Response Brief</U>), which shall not exceed twenty (20)&nbsp;pages in total. In connection with the submission of a Response Brief, a Party may also submit documentary evidence in support thereof which had both (x)&nbsp;existed prior to
commencement of such Mediation/Arbitration and (y)&nbsp;been shared with the other Parties at least [***] prior to the date for submission of the Response Brief. The arbitrator will provide each Party&#146;s Response Brief, along with copies of any
supporting documentation, if any, to the other Parties after he or she has received a Response Brief from all Parties (or at the expiration of such [***] period if any Party fails to submit a Response Brief). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Within [***] of the timely receipt by the arbitrator of each Party&#146;s Response Brief (or expiration of such [***] period if any Party fails to submit a Response Brief), the mediator will conduct a single [***]
meeting during which each Party will have present, in addition to its counsel, a person with authority to reach a binding agreement resolving the dispute. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">If the dispute is not resolved by mediation within [***] following the meeting referred to in (f)&nbsp;above, the arbitrator will conduct a single [***] hearing during which each Party will have [***] to present its
position. At the hearing, each Party will have the right to call up to [***] witnesses, [***] of whom may be an employee, consultant or other advisor to another Party. Each Party will notify the other Parties and the arbitrator of the identity of
the witnesses it intends to call at least [***] in advance of the hearing. Notwithstanding the foregoing, the time periods and other aspects of this provision may be modified if (x)&nbsp;the Parties agree to such modification, (y)&nbsp;the
arbitrator determines that such modification is reasonably necessary in view of the factual circumstances of the matter to be decided, or (z)&nbsp;if more than two Parties are participating in the Dispute and the arbitrator determines that more than
two of the Parties (or sets of Parties) are in good faith seeking different resolutions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">The Parties shall submit Opening Briefs and Response Briefs, as well as any documentary evidence, to the arbitrator in electronic form by midnight Eastern Standard/Daylight Time of the applicable deadline and, if the
arbitrator so requests, will also submit a hard copy to the arbitrator. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">There shall be no discovery in the Mediation/Arbitration (e.g., document requests, interrogatories, depositions, etc.), except as follows: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Opposing Parties may take a deposition of any declarant of the other Party and obtain copies of all documents on which each declarant relies upon in his or her declaration; provided that the Party(ies) taking such
deposition must complete questioning of the declarant within [***]; </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">As may be ordered by the arbitrator following request(s) of a Party; provided, however, that the arbitrator&#146;s decision to grant any discovery shall be subject to the following conditions: (a)&nbsp;the arbitrator
must conclude that the requested discovery will result in information that is necessary and essential under applicable laws to reach a fair and equitable decision; no interrogatories or requests to admit shall be allowed under any circumstances; no
more than [***] depositions of <FONT STYLE="white-space:nowrap">non-declarants</FONT> or <FONT STYLE="white-space:nowrap">non-witnesses</FONT> shall be permitted and the Party seeking </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">the deposition must complete questioning within [***] for each deponent; and no more than [***] document requests shall be allowed, and each request must identify the document(s) sought with particularity (e.g., a Party
may request a particular email sent from one individual to another on a certain date, but cannot request all emails sent by a particular individual). </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All discovery must be completed prior to [***] in advance of the hearing. If a Party refuses or cannot provide the requested discovery in a
timely manner (the &#147;<U>Refusing Party</U>&#148;), such Refusing Party shall lose its right to take discovery (or, if such Refusing Party already took discovery, shall lose its right to present the discovery obtained to the arbitrator) and the
arbitrator shall not consider discovery evidence presented by the Refusing Party during the hearing to reach a decision. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The arbitrator
will also have the right to perform independent research and analysis and to request any Party to provide additional documentary evidence that existed and was controlled by such Party prior to the arbitrator making such request. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top">Within [***] of such hearing, or within such other time to which the Parties and the arbitrator agree or the arbitrator determines is reasonably necessary in view of the factual circumstances of the matter to be
decided, the arbitrator will deliver his/her decision regarding the Dispute in writing. The arbitrator may but shall not be required to select the resolution or position proposed by one of the Parties. As part of any such decision, the arbitrator
may also mandate that the Party or Parties whose proposed resolution is further from the resolution determined by the arbitrator to pay some or all of the other Party&#146;s or Parties&#146; reasonable attorneys&#146; fees and expenses in connection
with the Mediation/Arbitration, as well as the costs and expenses of such Mediation/Arbitration (&#147;<U>Costs</U>&#148;). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top">Each of the Parties irrevocably and unconditionally submits to the exclusive jurisdiction of the [***] (and, if such federal court rejects jurisdiction for any reason, then solely and exclusively in the state courts of
the [***]) solely and specifically for the purposes of compelling arbitration or enforcing the decision in any Mediation/Arbitration, with the proportioning of Costs of any court proceeding to enforce the decision in any Mediation/Arbitration to be
established by the arbitrator in connection with the decision of the arbitrator. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing set forth herein shall be deemed to preclude
either Party from seeking appropriate judicial injunctive relief from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending a decision on the ultimate merits of any
dispute. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit I to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Confidential Common Legal Interest and Nondisclosure Agreement (copy) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit J to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Invention Management Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>First Amendment to the Confidential Common Legal Interest and </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Nondisclosure Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This First Amendment to the Confidential Common Legal Interest and Nondisclosure Agreement (&#147;First Amendment&#148;), is entered into as
of December 15, 2016 (the &#147;First Amendment Effective Date&#148;), [***]. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>The Original Parties are parties to that certain Confidential Common Legal Interest and Nondisclosure Agreement (the
&#147;CLIA&#148;), dated as of [***]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>pursuant to Section <FONT STYLE="white-space:nowrap">D-4.1</FONT> of the
Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Engineering, by and among The Regents, Caribou, TRACR, CRISPR, ERS, Vienna, Charpentier, and Intellia,
(&#147;IMA&#148;), [***] and having the same date as this First Amendment, [***] has the right to become part of the CLIA under the terms and conditions set forth in the IMA, the CLIA, and this First Amendment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in consideration of the covenants and agreements contained in this First Amendment, the Parties hereby agree as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">[***]. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Original Parties hereby accept [***] as a Party to the CLIA. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Each Original Party acknowledges that the CLIA is in full force and effect and that each such Original Party has no claims, causes of action, defenses, or rights of offset with respect to its obligations under the CLIA.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Except as explicitly set forth in this First Amendment, all terms and conditions of the CLIA shall remain in full force and effect, and the CLIA, as modified by this First Amendment, is ratified and confirmed in all
respects. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">This First Amendment may be executed in counterparts (whether delivered by facsimile, electronically by image or PDF or otherwise) with the same effect as if each Party had executed the same physical document. All such
counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the Parties, through their authorized representatives, have executed this First Amendment to the Confidential
Common Legal Interest and Nondisclosure Agreement as of the First Amendment Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signatures set forth on the following page] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED.&nbsp;ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d283294dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g283294logo1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global
Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY,
California, DUBLIN, Ireland, December&nbsp;16, 2016 (GLOBE NEWSWIRE) &#150; CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA), Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered
into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology. The parties to the agreement include the <FONT STYLE="white-space:nowrap">co-owners</FONT> of the
intellectual property &#150; the Regents of the University of California, Emmanuelle Charpentier, and the University of Vienna &#150; as well as key licensees and sublicensees &#150; CRISPR Therapeutics, ERS Genomics, Caribou Biosciences, and
Intellia Therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement, the parties commit to maintain and coordinate the prosecution, defense and enforcement of the CRISPR/Cas9
foundational patent portfolio worldwide, and each of the <FONT STYLE="white-space:nowrap">co-owners</FONT> of the intellectual property grants cross-consents to all existing and future licenses and sublicenses based on the rights of another <FONT
STYLE="white-space:nowrap">co-owner.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased that we have come to this global agreement with Intellia, Caribou, ERS and the <FONT
STYLE="white-space:nowrap">co-owners</FONT> and other licensees of this foundational CRISPR/Cas9 technology IP,&#148; said Dr.&nbsp;Rodger Novak, CEO of CRISPR Therapeutics. &#147;We believe that the Charpentier-University of California-Vienna IP
estate constitutes the foundational IP in the CRISPR/Cas9 editing space. Intellia, CRISPR Therapeutics, Caribou, and ERS view this agreement as enhancing the efforts to protect our shared intellectual property rights and support the ongoing
development of our product candidates, as well as those of our corresponding partners and licensees.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Through this agreement, we are ensuring
alignment in our efforts to protect and prosecute the foundational CRISPR/Cas9 discoveries made by Dr.&nbsp;Doudna, Dr.&nbsp;Charpentier, and their teams, which have transformed the genomics field and unleashed new therapeutic possibilities,&#148;
said Nessan Bermingham, CEO and founder, Intellia Therapeutics. &#147;This strengthens Intellia&#146;s IP position as we continue forging ahead with the discovery and development of therapies for patients worldwide.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rachel Haurwitz, President and CEO of Caribou Biosciences, added, &#147;We appreciate the efforts of the <FONT STYLE="white-space:nowrap">co-owners</FONT> and
licensees to finalize this agreement and are pleased to move forward as each of our companies develops products using this breakthrough CRISPR/Cas9 foundational IP.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This broadly enabling technology will be transformative across such a wide range of areas,&#148; said Eric Rhodes, CEO of ERS Genomics, &#147;and we are
thrilled to now be able to offer worldwide access to this important technology.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CRISPR Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary
CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company&#146;s multi-disciplinary team of world-class researchers and drug developers is working to translate
this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in
diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company&#146;s scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with
its R&amp;D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Intellia Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9
system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Intellia&#146;s combination of deep scientific, technical
and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn
more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Caribou Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies. The Company was founded by pioneers of CRISPR/Cas9 biology
based on research carried out in the Doudna Laboratory at the University of California, Berkeley. Caribou&#146;s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial
biotechnology, and basic and applied biological research. For more information, visit www.cariboubio.com and follow the Company @CaribouBio. &#147;Caribou Biosciences&#148; and the Caribou logo are trademarks of Caribou Biosciences, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ERS Genomics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ERS Genomics<B> </B>was formed to
provide broad access to the foundational CRISPR-Cas9 intellectual property held by Dr.&nbsp;Emmanuelle Charpentier. <FONT STYLE="white-space:nowrap">Non-exclusive</FONT> licenses are available for research and sale of products and services across
multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial
materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit <U>www.ersgenomics.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CRISPR
Forward-Looking Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements set forth in this press release constitute &#147;forward-looking statements&#148; within the meaning
of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the therapeutic value, development, and commercial potential of <FONT STYLE="white-space:nowrap">CRISPR/Cas-9</FONT> gene
editing technologies and therapies and the intellectual property protection of our technology and therapies. You are cautioned that forward-looking statements are inherently uncertain. Although the
</I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises
nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and
uncertainties. These risks and uncertainties include, among others: uncertainties regarding the intellectual property protection for our technology and intellectual property belonging to third parties; uncertainties inherent in the initiation and
completion of preclinical studies for the Company&#146;s product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials;
expectations for regulatory approvals to conduct trials or to market products; and those risks and uncertainties described in Item 1A under the heading &#147;Risk Factors&#148; in the company&#146;s most recent quarterly report on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> and in any other subsequent filings made by the company with the&nbsp;U.S. Securities and Exchange Commission&nbsp;(SEC), which are available on the SEC&#146;s website at&nbsp;www.sec.gov. Existing and
prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The information contained in this press release is provided by the company as of the date hereof,
and, except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking information contained in this press release. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellia&#146;s Forward-Looking Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press
release contains &#147;forward-looking statements&#148; of Intellia within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include, but are not limited to, statements regarding Intellia&#146;s
ability to advance CRISPR/Cas9 into therapeutic products for severe and life-threatening diseases and its CRISPR/Cas9 intellectual property portfolio. Any forward-looking statements in this press release are based on management&#146;s current
expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.&nbsp;These risks and
uncertainties include, but are not limited to, the risk that any one or more of Intellia&#146;s product candidates will not be successfully developed and commercialized, the risk of cessation or delay of any of the ongoing or planned clinical trials
and/or development of Intellia&#146;s product candidates, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product
candidates, the risk that Intellia&#146;s collaborations with&nbsp;Novartis or Regeneron&nbsp;will not continue or will not be successful, and risks related to Intellia&#146;s ability to protect and maintain its intellectual property position. For a
discussion of other risks and uncertainties, and other important factors, any of which could cause Intellia&#146;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#147;Risk Factors&#148; in
Intellia&#146;s most recent quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in
Intellia&#146;s subsequent filings with the&nbsp;Securities and Exchange Commission.&nbsp;All information in this press release is as of the date of the release, and Intellia Therapeutics undertakes no duty to update this information unless required
by law. </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><U>CRISPR Contacts:</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media:</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Paganelli</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">W2O Group for CRISPR</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">347-658-8290</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>jpaganelli@w2ogroup.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors:</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Brinzey</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke Partners for CRISPR</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">339-970-2843</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>chris.brinzey@westwicke.com</U></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Intellia Contacts: </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media:</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Mound Smoter</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief External Affairs&nbsp;&amp; Communications Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-706-1071</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>jenn.smoter@intelliatx.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors:</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Graziano</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+ 1 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">646-378-2942</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jgraziano@troutgroup.com</U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chad Rubin</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trout Group</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+ 1 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">646-378-2947</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>crubin@troutgroup.com</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Caribou Contacts: </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greg Kelley </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Feinstein Kean Healthcare </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">404-836-2302</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>gregory.kelley@fkhealth.com<B></B> </U></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>ERS Genomics
Contacts: </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacDougall Biomedical Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mario Brkulj or Dr.&nbsp;Stephanie May </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct: +49 89 2420 9345
or +48 89 2420 9344 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> <U>mbrkulj@macbiocom.com</U> or <U>smay@macbiocom.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g283294logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g283294logo1.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M" ". A # 1$  A$! Q$!_\0 V0 !  $$ @,!              @&!PD* @4!
M! L# 0$  @(# 0              !08$!P$" P@0   & @$" P0""!$%"PT
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M2.W:M@,LL=-(ACAR5XANWKVK42^L?5BP;K]67TLJ7J79*=#M&U*!2J]KC;T
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M44O&B"+A(OENA W5/N*)>C)&M%'"JBMJ6K.^!OK4:[_/FW';VRS4!1O*Z-Y
MVNW6*[ZT?R<=)E'5FTY-U.?,9N4U5$/555%F#4Z2D%. 0S] Z:2H&+T\QI:0
MP4*RN_6SMK:QVOPNX@V#6.Q:+L2#?<AI1^REZ1;8&UQSIBXU5910>I.X)^^2
M,U4$X !^O0!$ 'Q$ PNL)VDU6X90/W!TG\4:W]YF6%CE5=A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M-?U>/\2;Z./["Z<_CXVOA
M93/R[O:MDOG#Z>'%'U#]>LM=\G];M[8W@SNW--N$.]7KNPJ%(/B)INW]/MC$
M!=,/BR(D!=JL1PQ<]A?.04[2]"QPZGM6&;4WU3STT=>WME;;C.;]W-!13TKM
MAKN]W6OQ]1=ID4(H5C8QI=3K,[-L![  Z)7C9)8H=%"F#J D<=Q61[D)Z/O%
MGD1R0XB\EYIW?*%9.%#"CQ.EJ-K.0KE;UHUA]>W-"[5J(EJXK69!R>-:OFJ;
M;R6KIJ4&A0(7H/O879LA:TMIU4VN2?&#1?+O5DWI;D3K6M;2UO/"DNZK]C;*
M"=C)MN_X&>K\LS4;3%;L4=YAOAW[%=%RD!S !NTQBB75KJ+$YPQ^KX<.>!G*
MZ)Y6Z"O6\T)N$@+U78^@7*TUZRT]!A?(4\*^#XLM5C[*NI'(J"9L==XL?NZ>
M88^%VWU%"%<GCMZ%O"7CYI?E9Q^!+96V-4\QIN!G]O5S9UK;+'(^K2TP\A3U
M63IL13Y*#&/D9<7*1A56.59!(>[H!@,75SMRA3K?ZJ+Z:5#VC'WR9F=^;,JD
M/+DEX_4EYN]?&EO#)KE<)QEF>5RH0-FL$,!B% [<7B/Q!"]JYE2F.!B-=M62
MWDCZ37&WD[RFXL<M;C,[%JU[X@M*M'ZHJU!E:]!Z]^7TZVJ7"$8S<"YK$BZ5
M9MWQBH FU=-"E:IE(7M$.["YW:$#M64#I[?LX7F!0D]ZQESWI6<?K!ZCU8]3
M][9]H$W]4ZTA5(ZMMYZ#3UBM&-Z%/:[*H[@S5M2<4>#"6%903%DBD^)*0W;V
M@)1+E7TYF\#N+?/S6R6KN4&KXN_0D<NZ?5B;37=0EUH\L[;_  J\M2[=%*-Y
MB"=N$>A5TRG,U=%*4JZ2I2@7"[--%@(EOJA_ !R[<FA=Y\K(2+65451B3VC7
M$HFT[SB)"I.5]<(JJ DGT*!E .H/3J)APN_F>"VIH:,1A(>*AFYU%6\1&L8Q
M!182BLHBP:I-$CJB0I2"H<B0";H !U]@87DNRPB81,(F$3")A$PB81,(F$3"
M)A$PB81=/87LK'0<H^@XM":F&K)=>.B7,DE#MY!VF011:K2BR+A)@FJ;P%4Q
M# 3V]!SLP-<\!QHTG4TK]BZ2%S6%S!5X&@K2OT]BL]6+]N>4GXN/L6GZW 0K
MIP*<C,,]LQ,ZYCT?*4."R,2A -%GYA5*4O850H]#=>OAF2^&V:PEDCB[NV$?
M;58L<]VYX;)$UK.T[P:?135=5R+Y+ZTXU1-7E]DWG7]':6N5>Q,4XO\ .SD&
MUD';%B+]PWC5(.K6A5PZ20]\Y5"(E GB!A'PRKYSE'&^+Q1S\DNV6D,KBUA<
M"=S@*D #70:K87"_3;G_ *CW$]IP+%SY.YM8VR3-C(!C8YVUKC4C0NT73\<N
M6.J.2SRW,M:[#UI>%Z<VA'4PEK^PV&<5C4IU6428J2I9RGU8K9-V>)6!$4A7
M$XIG[@)T#N\L%S#BG*72LXW>QW;X TR!H(+0^NTFO?M=]2R>:>E7J3Z;Q6\_
M/L1<8R&\<]L!D+3YAB##(!0GX1(RO]04ILL2H*81,(F$3")A%P,;M]H@ ?9S
MS>\C1H)<N=%SST7"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(OG\_6I=G7O2WJB\/MMZNL;NH;'UOQBK-NI%I8HLW#ROV.+W3
MM91A*-4)!N\8JK-C"(@55)0@B/B X65"-T9;XK$"'KT^KJ'7NYO;%Z^WQKFM
M/ /^A/LPC8VLT>*E<OS]'JZ?SW-C?]'-:?O)PNU(OPI^?I]70/;S=V+^C^YS
M6G[RL)2+\*?GZ?5TZ]/Y;NQ>OZ'X.:TZ_J?@3A*1?A3\_1ZNOL_EN;&ZC_\
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MB@(Y/W^ RV-M67MY"8[62@!J#4D$@=>X**L<UC\A=36EM('7$3M6]H'[=5-
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MEG"PCU5787"811\Y6_DZ;=_%!Y_GF^9F/_.Q_P!2P<G^0E_H*Q,<#?RE*O\
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MODH3\3=M.G@.J\\7%)&YY?"R*H'PNW5Z]=32BBAZEW[N-6?BI8?ONPR0P?\
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M,(#[!Z:]=#T'[ AX9 ^B9#<Q-(?B;;5 []3U4CZU[G8&WC&C77(!/=THK0:
M^KM?PT\>].[//SSW=6DMH:FH]U/4FE>4>P<$2VUB.FA@&P*7UJ1U&1POO)*
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MOM*[+T.U"P7K0<VH.5'X.5<Q7)-FBS6]Q91RQWU!O'*)"G[3&,DV*)Q  ^U
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M-._O.PF]W>5+I!!%JBBV;(I-V[=)-!N@@F5)%!%(@)I(HI$ I$TDR% I2@
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MJI:[AD;!=)IO P[B<KM;1?.DG2J1YNV3;"MUV/ K1!PJ"LI-R:#<AA*!"F4
M3"4O40G[[(6>-@%S?2". R,8":_'(\1L;H#JY[@T>)U5+PN"RW(;PX_"PNGO
M&P33%K2T$1P1/FF?[Q HR)CGD5J0* $T"]><V+2JU<*-0)R?:QUPV6:R$HT&
MJD[.YL1JA$EG;(#15%NHU1&*B3 N?SE$NXO@3N-X9TN,G86E[;XZXD:R]NR\
M0L-:O\MN]]-*>ZW4U(TZ57I8\=S63P]]G[&W=)A\8(3=2@M A%Q)Y4.X$AQW
MR>Z-H=0]:#54KMK?&K=&,XR0VA8']>82Y)55H\:U*Y69J1"$1;.)1Q(KU.OS
MB<.V:(.R'%1V*!#%[A*(]A^W#S7(L1QZ-DN6D?'&_=0B*604: 7%QB8_: #6
MKJ#KW%2O$N!\IYS-+;\7MX[B>$QAS77%O"XF4N# P3RQ&0N+2*1[B#2H%17G
MJ7>NK]Y,)*4UA/OK#'101AG3UU5+C66RB<PW6=QJ\>K;("#++M7;9 QP5:>>
MF!>G4P=Q>O.&Y#B>01.FQ,CY(F;:DQ2QCW@2TM\UC-P(%:MJ/'4+CEO!>3\&
MGCM>3V\=O<R[]K6SV\Q!C(:\/$$LOEN:2!MDVFM: T-*F0V/27.Q)'4Z%@:J
M;#B:C'7N1K (O >-:E+RKZ#CILZYFP,#-W4K&KH@4JHJ@9,1$H (".4W*8]V
M4=A6RM.49 V8QZU$3G%@?TI0N:1UKIT48_C>;BX['RQ]NX<=EO'VK)ZMVNN(
MXVROCI7?5L;VN)+=M#H:Z+J]I[AUGI2N)VO:5QBJ?".)!K$,%7XN7+Z8EWIN
MUI#P,+&MWLW8)=ST$2-63=PX,4IC 3M*80\LQG,3@+7YW,3L@MRX-%:DN<>C
M6,:"][CV-8USCJ::+)XMP_DW-<D<3Q:SEO+YL;I'!E V.-OQ22R/+8XHV]LD
MCV,!(%:D+\=4[CH.ZX)_8]>R,M(1L7+*P<B$W5+93I!I)HM&;\S=6)N,)!2@
MD,S?HJ%5*B9$Y3]"F$0, <8?-X[.V[KK&N>Z)C]IWQR1.#J TVRL8[H0:TH:
MZ'JO3E?#L_PJ^CQW(8XH[F6(2L\N>"X8YA<YE1);RRL^)C@6EP<*:BA!-(W+
ME!I&A[#8:JL-P<#?'RL(DM!P-6M]L&"/97 -:]^%C^K0,S&5$LRJ;JW&36:@
M=+[K_P D GS"ON68''9)N(N9G?J#BRK&1RR;/,-&>88V/;%N/P^86U&O352V
M&],.;9[CTG*L?9M_06"0B66>W@\WR1NE\AL\L;[CRQ\?DM?1WN_'[JO]EC5!
M6#;U_P#C[R)W[P<?(:!F;$Z;:]LZ-XVMJRMF7*^VKKR/8."O6146A1=S)ZB]
M%.4",_Y-ZFB<>TZJ21#7KTYRF+QG)6291C7QN% 7#0$]/K5!]1\=DLCQQ\>,
M>YLH-2!U(7SOP$!^D?:/MZ]0$/ 2B ^)3%$.@@/B'3H.?5[7-?&)6$.C[QK]
MR^47U:\PO!$E.A%%RZ]/T/\ */0/U?HSC;'*W;("8SU'0KP\N8&C*M?WTJ L
MVFA?0+YQ\C>/NNN0^OY/3#2#VA !::Q4+;;)^"M@P#E=8D3(/O+JTA"MOG35
M('"!/B3"5%0@G$HFZ!K3)>I?'\1DI,2^&1SH74<>H!\".M%L_&>EF<RN,CR+
M;E@\T58-!4?L5%6;T%?5*@I5O"?R<&=@3?ND&"<W7]FZYDX%#XI8K;XQ^L>P
MM'S6/;E/YBQS-N\J8"(%$0Z9V9ZG<-8P3M<_S@#[A8\@Z=/AIU0^E?,HY1&W
M:8BX>^'L!&O7X@5]!#B_JR;T?QVT?IVR3RUIG]8ZHH=&FK(NX5=#,2M;KK&,
M?NDG#D1=*M1<MS B93WQ1 O7QZY\W92Z9?Y*>^C:(XY97.#!T )JOI3&6TUE
M8PV4SC(^*)H+SU<>WZE9GU'3 '"?D*4>H_ZD(#T_1Z6.#^GV9<O2LM9ZA8N2
M0;H1,_<WM(\MW;V+4G^XD7$OHQGX;-XCNS:Q[7%I< 3<14T UZ*-^WM1\U;A
MH*0C)K;&H[;1%:7&OK1K^LTJ9UY9KM2&,6VDIFE,[ZZF+62!<S48V% RY&8"
M?Q+W)@81">P6<X%8<N\_&V4T/(&W+FV]PZ5LC()7N(#I(@*N'3V==51>:<=]
M6KO@DK\ADK6]X[#:LN+FT9 627-O T2.A;(11I<.I.KB*!7&W7L2H;4],/8M
M\H<>YAZC8N.<JO PCM/L<P;!G&_+"P:PE$Y%#PRC,S;O 1!0$P,'@.8'&\7?
MX?U=MK').$E\S)L+W-Z.<][GEPIV'=6G9T5AYQF[+D/^W&^SF-C='87&#_MQ
MT.Z,.:S9$12M6"C":4TJJ YA>/$WB@C-=R>NE=I\7TMH&4'JQ/3C,V9O^> ^
MU"%^>E:>?W^YT[>OAF?PYD<W..0,;_U!ME>/@/0^9O=0-[W4!H.NI4%ZJAS?
M2WC$%T\Q8-V0Q0NR= 8"QCG->.H;O !J*#KT65@AVQ4R$0\L$O+ $B)$ J7E
M 4 +Y0$#M\OM#W>GATZ=/#-./$C9?.G+C(!4D@T'?KWUZ]J^F8G6;HA!#L;$
MX>Z!05;V%H[6TZ$:4Z:+'/7@:E]338:=-[2,5^+M65VV5@!?)"V)W-=*C#+%
M3^YA.C7@.! /T4%K]C-HW#W'TELI,C[UR,G*8 X>\87-&YS6G4M#@:FFA6@\
M8 /]PUTW /:VS. ;\XR,@@7#7[8C+MT;(V,UH[WJ#HO9D-#;&@-A[+VKP\WE
M2HE2\VQ:3VAJV]12%UUI(["CVK=I+.6\M /"62DV)RW!(KQ$GF@!Q QBEZ@7
M,2/DF&N\3!C>;6$DGE#9#*V39((]::$%KFT!(J0?"NJR;C@66L\_D>4>D^6M
M;5M[<L-Y;S-,UO+(P4<=S2?*D<: ]#57'XY;NFKY?=IZRV=K"$UEO[6Z%8?W
M8M:>(3E=NM9G6[HE1M<#8A;-91W&J@V42^'> *K3[0!$.N8')N.6N#P]GD\!
M=/N^,76_R-]08W@CS&$'X=O:X4!HIST]YID<_F,GQ[D>/_3N:XX-,[8RWR9V
M$?VY-P)+@\?#J:55N/33&/'3>PEW_ECLQ??NZ!VV93M^<!< N3XJ!)83A\0!
M2P)6OPP']WRNO;^NR>]7'.;R*S;:@MPAQ5L;8#_+<-@\TL[/CJ#3JJO_ +</
M*=Q*_FNG>9R3]:NQ<[@1,TF4F)D@/O!K6:,KI3HIRVV0HS!&%<W)U6&:!IQ@
MA K6@\6BD-D7$Z44G$*2HE2"=5,<Q6X(B"XB(@3Z<UM:/OIG/CMA,!L.\-:[
MX>]U.C:]^A*WAE;C%6KF2Y-UM%*Z0!IEI7<>R,'4N[]OA50SNX]WJ/:)'M$!
M'B_N$H=?I$;C5 ']+H/AFP\9&8_27(1G7;EK>I[-8G]OT56GN1-=_P#T-A/=
MT''K\5[R^2+;0?\ "?VJUVW8W<\GZAB"&CK30:E:$^)#-22D-B5J5M$.XA0V
MB[*HT9,HB3BG*$B9X*1P5,<Y/+*8O;U, A,XRZP\'I2UF;9>R6GZVYP;"YC1
MI T$U()KJ!T[NXJI<ILN5W/^XADO#)["URC>+;7R7,4DM6F[W-:&LD9W.-:>
M!/136TI%\@8EM._P\7#6MM<*N68UM37-2F:LBQ;%36"0)*EF)J7,]577$ADC
M)B0"E P" ]0$-8Y:3CQ\EN MKF%PC ?YTC'NK0?A ^JA[-5O7B=MS2!CH^67
M-M,\ BD$+HVD@FI&XDZ^WV:+'G8-#1W(7DSSRJ9)-:K7.OJ\:KKJZ]L_<EJ)
ML*$HTHM"3K-P7JL5HJL (O$0\%VIS%$!$ S<%MRBXXQPGCET8_-M727[)VD>
MY/;R2-#HBW\3!4AU.I%"OG*^X):\_P#4KF>(#G6V08S%W-I,W22*XMVN<#O'
M2.1P <RO2JI.Y;[F-QAQ(JNQXQ&K[YT[S9UM3=R4\!*0$I8D'8RQUOAD^O5>
MJ71N7XIFL4!3*)CI]?=*)LBQXS#@;K.9/$DR<9ON/W$ML^M:L#V_VR1UDC/N
M.;3<2.BPL_SNYY=!QC'\A8+;F=ARB&"[MSIT#@V6OP[)0 \$&@K3127F0:K>
MIU4OPQ! 6Z'%N85T^5[V^4:?4NY"WT\2!Q[!FB1 H^9V_= ;"/T93H9'P^D<
MQL"X7#\DUMVYO41-%80X=2TNZTZ=31;*NY62?[A8H<\ ;3]$:<>'TVOGWUF\
MLG2K65->WL-5D-=G8F;.@=@C\*""GQ/Q!2BV,W\LPK>>53HD*'E=>[N]WMZ]
M?#-8"6<.'DAXEJ-I )-:Z;>\^Q;XF,!B=\TU@M0TU+Z;*4UW5T#:=:Z+&GZA
MKV EN)%;7UD_JR\0ON32:=4D('X-Y44W(;#CT&:B!(50C->.:R)/NR:!B]0(
M<H"!O9MSTG;-;<[G;E/F0X6%UOII( 8']KN_MKK0KYY]?9XLAZ7Q.P;[5[79
M2Q;$YH+X"[YI@T$9;NU[G4!%3H%?>A5KFNRMT OL?:.@)NC(.3FL<+4M:VN&
ML3UB#5<J:,7*2%LD&C-P#H4Q$YTU0[0$/:/4*EDKOAILWLL+7(#(DG8^66,Q
MU[MH:#4CH:TH"MA<=QWJA;9&WESE]BG86-H\R.&![) -AH0]SW BO4 5UK73
M7U^0FE(K:UYUW9*7MTVH>1&N(ZQ2%#F6",1/.7M6E?A&=EC+#1Y-=,]AJ3IP
M"(+*$$GD*&\#]1[1[\9Y'<X.PGQU]9,R'$;O:+B(M=N#VZM,<K:AC^HJ>M%&
M\XX99<GS..RV'RCL;Z@8UDGRSHW-EW-DT<);:O\ =C UH11M2K9,MS;RU/LS
M4>O.6M,UA;8;8UM-3]9;SUD@[;(1VP%V#E:-B[)3+"1P\K#Z<8IJII/(]PHE
M]L4?=$>DT>/<>S.$O,WPR2\MIK.W,UQ9SN#@V$.#=S)6^Z[:7 ;#[_AH:5^V
MY7S#BO)L9QOU3AQU[99"X,%KDH&[?_=4W,AEAU\E\C07-+?=T(+JT"R,(B!B
MF,'7Q,/41\1$0  ]OTYK1KMU0?B%*^%0#3ZB%OQI!JX-VDDU]HT_8OVSLNR8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3"*"?$Q%TEO3G^=P@Z227Y*UQ5J=P
MBNDDX1#0^J416:G5(4CA(#)=@F()B@).WKU#H&NN%,D9R'DQ>UP:[+L(J" 1
M\E:BHKU%12H[13L6]?5E\3N#>GXC<TN;QF8. ()!_5;\T<!J#K6AH:&O:N?/
M^)L$YK#4D75IAU6[ \Y4<<48JSLX-M95:P\-L>-!&PF@GP#'R:42<05,DY$K
M<X%Z*"!>N=O4F"ZN,19063W173LQ8AL@8)#&?/;238?=<&?$0[W3371<>@%W
MC['D^7NLK"RYQ[.*Y@R0.E=")V_)OK#YK??89![H<RKQ6K02K9P6O]R4SG/Q
M^5VKNQ]NXKS0W)8D2]/JZJZ\:U84[)H,7*!UJF*B4DM-]Q!*5R8HI T$4NO<
MITA+;%<@L/4?&/S60?D6'&7X:[Y>. 1?W+*HK%HXO[-W38=O4JT7_(.&9KT*
MY SBF$CP99G\-YC1?3W;IZPY6AI/0L$6M2RM?,][HU5;ZFXNB<8VB[275KBS
M/>O'-\%G2C22_P""Q&6Z:8Y4LZT:J0[=XVKQ$A=JD6#R3$1$%! G4<D?5H2'
MB33$\Q.;DK ^8&[O+I=PGS"TZ$1_&0?=H-=*J&_VR^4?4Y[)H1<L?@<PWR"\
MQ^>78VY:( \$.:Z8GRVEOO N&W6BOEQBMY;54IXJO(^%Y,2$;83E<VZ%JE9I
MR4(V=LFQV5?6BZJ)F"QTQ147!<X^:H"O0?=*7+)Q2Y?<6+VRY1F5F;)K*V..
M+:"!1A;'[NE":]37P5']3\0<7EX"SC<_&;>2W&VWDGGN#(6N<'2A\_O@&H;M
M'NC;7J2HS<B*9N^X<O&"6A]I!J2Y,^(%U79S;RBPETAK ]_A.A/E=9DC3Y#-
MX1!:1%-4[IN!W29"B($,4! :ERC'\BO^:,_TW>?(WK<+*0\PLE:\^>S;&[?H
MSWJ'<WWJ#H0ME>G>9X/A_2.1W/,5^KX9_+[8.C;=2VTD3?DI=\S/*-92&5:&
M/HPG0D'47YX+K4S^2QJ>-I%>FZ@RK\7*5^PU"RO'<A8JML"+GY5+8\+-O7J+
M=9X^;W@S\WG%32163.51$A$3)E"R>G_R+>(645A%)!'&QS'QR$E\<P>[SVN)
M J1-OU  (H6@-("HOKHS-#U3RUQG+B"\GN)62PW$+6LAGM'Q,-G)&UI(:TVW
ME#:2YS2"UY+PXJ(VYH38/*3=N[F,/IL^SM0:WUS9^-E7DGE^AZ(C&;6NK2/E
M]L7VOI3,,^<R$K4VQ(6)8OD#$*T>,WI4Q,8QA+3<[:9'EV?R$3+$W6$MK1]C
M&XRMBI<3!K[B9FYI)=&/*C8\?"]L@%233;?#+WC_ *7<)PD]YF1C.89+(PYF
M9C;62Z+[&V<^.PM93'(UK&3DW,\D3@3)') 74  ,SN'FS+=LO1M>_A*9*QNW
M=>/I74NWV*I% *78VNW/R"=DVJY^I'T=9$T$91LX2$R2J#THE'IX!=^$96^R
MO'HCEFEF:MG.M[D'_P ^$['N![6R4$C2-"UXHM,^L/&<1QKG-Q_IIXDXCD61
MW^/<"/R=VWS8F.'5KX270/8ZCFNC(*A$\TMM7=_*7U%]=P.RXK6>K;ZUT)5=
MAF7UD6W6ZQ1LSH:)CGR=+GYN>9U>#*:(.Y:+J+1<HHDLJ50GEG3 !H#L#F<_
MR[E&-M[IEIA[GY2.:MOYDL@=9QM/E/>\1L&W<TDQR$$U%"*+=\7-.*<(]+?3
MGD5_C)<GRJP=E)[2E[\O;POCRLKVFYBBB=/(?,#)&AL\ <T%KMS75&6&KUV-
MJ%9KM3ABKEB*O!1%=BBNES.7)8V$CV\:Q*X<G]]PN#5L7O./B<W41]N;DM+:
M*RM8K."ODQ1M8VIJ=K0&BI[30=5\G93(W.7R5QEKS:;NZGDF?M%!OD>7NH!H
M!N<:#L&BQ&^F=<G+>A:,J$KRUAIT?P DHYMQC7U[48>PUE^V.\>)LUK4B!+<
MY6K3-HL<Q'!0%8ANX_@ 9I3TBN9H</C[.YS#)*VQ:VP,,3'Q.!<=ID']UQ8
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A1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
